CONCORD BIOTECH LIMITED

B-1601-1602, B-wing Mondeal Heights, Iskcon Cross Road, S. G. Highway, Ahmedabad-3800015, Gujarat. Phone: +91-79-68138700 Fax: +91-79-68138725 CIN No.: L24230GJ1984PLC007440

Email ID: complianceofficer@concordbiotech.com

February 10, 2024

To
The Manager, Listing Department
National Stock Exchange of India Ltd.
Plot No. C/1 G Block,
Bandra-Kurla Complex, Bandra (East),
Mumbai -400 051
Symbol: CONCORDBIO

To
General Manager, Listing Department
BSE Limited
Phiroze Jeejabhoy Towers,
Dalal Street,
Mumbai – 400 001
Scrip Code: 543960

Dear Sir/Ma'am,

Sub.: Press Release- For the Third quarter and Nine month ended December 31, 2023

Pursuant to Regulation 47 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith extracts of the Standalone and Consolidated Unaudited Financial Results for the Third quarter and Nine months ended December 31, 2023 as published in the below Newspapers on February 10, 2024.

The Details of the publications are as follows:

S	r.No.	Newspaper	Language	Editions
	1	Financial Express	English	All
	2	Financial Express	Gujarati	Ahmedabad

Further, in terms of Regulation 46 of the Listing Regulations, the aforesaid financial results are also uploaded on the website of the Company (www.concordbiotech.com)

Kindly take the above on records.

Thanking you,

For Concord Biotech Limited

Prakash Sajnani Company Secretary and Compliance Officer M. No. F6242

Encl: as above

Regd. Office & Plant: 1482-1486, Trasad Road, Dholka, Dist. Ahmedabad-382225. (India) Phone: +91-2714-222604, 398200 Fax: +91-2714-222504 Website: www.concordbiotech.com

CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat **Phone No.**: +91-79-68138700 || **Fax**: +91-79-68138725 || **CIN**: L24230GJ1984PLC007440 Email Id : complianceofficer@concordbiotech.com || Website : www. concordbiotech.com Regd. Office & Plant : 1482-86, Trasad Road, Dholka, District : Ahmedabad - 382225, Gujarat, India Phone No. : +91-2714-222604, 398200 || Fax : +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS

FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023										
	(Rs. In lakhs except per share data)									
		Standal	one (Unaud	ited)	Consoli	dated (Una	audited)			
SI. No	Particulars	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022			
1	Total Income from Operations	24,079.65	69,796.98	24,068.29	24,079.65	69,796.98	24,068.29			
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27			
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27			
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,455.30	20,751.75	7,907.55	7,757.27	21,308.69	7,736.83			
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(64.87)	(40.36)	17.94	(64.87)	(40.36)	17.94			
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16			
7	7 Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year. 1,28,151.88 1,28,151.88									
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations - Not Annualised)									
	1) Basic	7.13	19.84	7.56	7.41	20.37	7.40			
	2) Diluted	7.13	19.84	7.56	7.41	20.37	7.40			
No	otes : (a) The above is an extract of the	detailed for	mat of Unau	dited Quarte	erly / Nine M	lonths Stand	dalone and			

Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) .e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com (b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with

Ind-AS Rules /AS Rules, whichever is applicable.

(c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 08, 2024. For and on behalf of board of directors of Concord Biotech Limited

Place: Ahmedabad **Ankur Vaid** Joint Managing Director & CEO - DIN: 01857225



ULTRACAB (INDIA) LIMITED

Survey No. 262, B/h. Galaxy Bearings Ltd., Shapar (Veraval) - 360024 Dist. - Rajkot Gujarat CIN: L31300GJ2007PLC052394

Tel No.: +91 2827 - 253122 / 23 Fax: +91 2827 - 252725 E-mail: cs@ultracab.in web: www.ultracabwires.com

EXTRACT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED AND NINE MONTHS ENDED 31st DECEMBER, 2023

	(Amt Rs. in Lakhs)										
Sr.		Q	UARTER ENDE	D	NINE MON	YEAR ENDED					
No.	Particular	31.12.2023 UNAUDITED	30.09.2023 UNAUDITED	31.12.2022 AUDITED	31.12.2023 UNAUDITED	31.12.2022 AUDITED	31.03.2023 AUDITED				
1	Total Income from Operations	2214.92	3133.45	2461.54	7974.11	8268.42	10767.19				
2	Profit before Exceptional Items	214.02	194.79	232.50	551.88	571.13	780.98				
3	Profit before Tax (PBT)	213.73	195.58	229.04	552.38	568.60	777.13				
4	Net Profit after Tax (PAT)	164.34	153.32	157.74	420.78	409.40	581.70				
5	Total Comprehensive Income for the period	164.34	153.32	157.74	420.78	409.40	581.70				
6	Paid-up Equity Share Capital FV Rs.02 each	1908.45	1908.45	1908.45	1908.45	1908.45	1908.45				
7	Reserves (excluding Revaluation Reserve)				-	-	1289.91				
8	Earning per Share (Face Value Rs. 02 per share) a) Basic (Rs.) b) Diluted (Rs.)	0.17 0.17	0.16 0.16	0.17 0.17	0.44 0.44	0.43 0.43	0.61 0.61				

1. The above is an extract of the detailed format of Unaudited Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligation and Other Disclosures Requirements) Regulations, 2015. The full format of the Unaudited Standalone Financial Results is available on the stock exchange website (www.bseindia.com) and Company's website (www.ultracabwires.com) 2. The above results are reviewed by the Audit Committee and were approved and taken on record by the Board of Directors at its

Place: Rajkot

For and on behalf of Board of Directors of **ULTRACAB (INDIA) LIMITED**

Mr. Nitesh P. Vaghasiya Chairman & Managing Director

DIN: 01899455







Place: Ahmedabad

Date: February 9, 2024

PSP Projects Limited

CIN :L45201GJ2008PLC054868
Registered Office : PSP House, Opp. Celesta Courtyard,
Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058 Website: www.pspprojects.com

Extract of Unaudited Consolidated Financial Results for the Quarter and months ended December 31, 2023

Nille Months ended December 31, 2023 (< in La							
			Consolida	ted			
		Quarte	r Ended	Nine Months Ended			
Sr. No.	Particular		31.12.2022 (Unaudited)	31.12.2023 (Unaudited)			
1.	Total Income from Operations	71,118.31	50,659.07	1,85,617.46			
2.	Net Profit for the period (before Tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	4,204.40	4,824.99	14,468.84			
3.	Net Profit for the period (after tax, Exceptional and Extraordinary Items before Share of Profit/(Loss) from Joint Venture)	3,106.66	3,532.82	10,737.75			
4.	Net Profit for the period (after tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	3,108.32	3,536.01	10,745.06			
5.	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	3,110.62	3,538.31	10,751.96			
6.	Paid-up Equity Share Capital - Face Value ₹10/- each	3,600.00	3,600.00	3,600.00			
7.	Other Equity excluding Revaluation Reserves	-	-	-			
8.	Earnings Per Share of ₹10/-each (in ₹) (Not Annualised)						
	Basic	8.63	9.82	29.85			
	Diluted	8.63	9.82	29.85			
No	tes:	•	•				

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09, 2024.

2. Additional information on Unaudited Standalone Financial Results are a	as follows:		(< in Lakns)		
		Standalo	ne .		
	Quarte	Nine Months Ended			
Particular		31.12.2022 (Unaudited)			
Revenue from Operations	69,661.92	49,739.28	1,81,332.80		
Profit/(Loss) before tax and Exceptional item	4,397.86	4,815.39	14,636.12		
Profit/(Loss) after tax and Exceptional item	3,251.85	3,529.50	10,864.77		

3. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL; www.bseindia.com) National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: For and on behalf of Board of Directors

Prahaladbhai S. Patel

of PSP Projects Limited

Chairman, Managing Director & CEO DIN: 00037633

KIFS FINANCIAL SERVICES LIMITED

CIN: L67990GJ1995PLC025234, Email: cs@kifs.co.in, Reg. Off.: 4th Floor, KIFS Corporate House (Khandwala House), Nr. Land Mark Hotel, Nr. Neptune House, Iskon-Ambli Road, Bodakdev, Ahmedabad – 380054, Guiarat, India, Ph.: +91 79 69240000 - 09, Website: www.kifsfinance.com

EXTRACT OF THE STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

			(₹ in lac	s except EPS)
Sr. No.	Particulars	Qtr. ended 31-Dec-23	9m ended 31-Dec-23	Qtr. ended 31-Dec-22
		(Unaudited)	(Unaudited)	(Unaudited)
1	Total income from operations	1,363.02	2,964.84	727.31
2	Net profit / (loss) for the period (before tax, exceptional and / or extraordinary items)	193.92	611.64	117.01
3	Net profit / (loss) for the period before tax (after exceptional and / or extraordinary items)	193.92	611.64	117.01
4	Net profit / (loss) for the period after tax (after exceptional and / or extraordinary items)	145.84	459.89	89.02
5	Total comprehensive income for the period [comprising profit / (loss) for the period (after tax) and other comprehensive income (after tax)]	145.84	459.89	89.02
6	Paid-up equity share capital (face value of ₹ 10/- each)	1,081.80	1,081.80	1,081.80
7	Reserves (excluding revaluation reserve as shown in the audited balance sheet of the previous year)	-	-	-
8	Earnings per share of ₹ 10/- each (for continuing operations)			
l	Basic	1.35	4.25	0.82
	Diluted	1.35	4.25	0.82

results filed with the stock exchange under regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the unaudited quarterly / half yearly inancial results is available on the company website at www.kifsfinance.com and on the BSE website For KIES Financial Services Limited, Raiesh P. Khandwala at www.bseindia.com. Managing Director, DIN: 00477673, Ahmedabad, February 9, 2024

HINDUJA HOUSING FINANCE કોર્પોરેટ ઓકિસઃ નંબર ૧૬७-૧૬૯, બીજો માળ, અન્ના સલાઈ, સેદાપેટ, ચેન્નાઈ - ૬૦૦૦૧૫.

બ્રાન્ય ઓફિસ : ત્રીજો માળ, ઈફ્ફકો ભવન, મારૂતિ કોમ્પલેક્ષ પાછળ, પીન્ટુ ગાર્મેન્ટ પાછળ, શીવરંજની ચાર રસ્તા પાસે, સેટલાઈટ, અમદાવાદ-૩૮૦૦૧૫.

નિયમ ૮ (૬) અને ૯ (૧) હેઠળ સિક્યોર્ડ અસ્ક્યામતની જાહેર હરાજી વેચાણ નોટીસ ક્રમ ટેન્ડર

હિન્દુજા હાઉસીંગ ફાઇનાન્સ લિ.ના સિક્ચોર્ડ લેણા તે અધિકૃત અધિકારીએ તે નીચે કોલમ નં. (સી) માં આપેલ બાકી રકમ અને કોસ્ટ અને ચાર્જેસ સહીત આગળના વ્યાજની વસૂલાત માટે ધી સિક્ચોરિટાઇઝેશન એન્ડ રિકન્સ્ટ્રક્શન ઓફ ફાયનાન્શિયલ એસેટસ એન્ડ એન્ફોર્સમેન્ટ ઓફ સિક્યોરિટી ઇન્ટરેસ્ટ એક્ટ ૨૦૦૨ હેઠળ પોતાને મળેલ અધિકારોની રૂએ નીચે જણાવેલ સિક્યોર્ડ અસ્કચામતના લીધેલ કબજાના અનુસંધાને, દેણદારો/સહ–દેણદારો પાસેથી લેવાની થાય છે. નીચે હસ્તાક્ષર કરનાર દ્ધારા જેમ છે જ્યાં છે, જે છે તે છેના આધારે અને જે કાંઇ છે તે છેના આધારે અહીં વર્ણન કરેલ, ફિઝિકલ કબજામાં રહેલ સ્થાવર મિલકતની ખરીદી માટે બંધ કવરમાં ઓકરો મેગાવવામાં આવે છે. જેની ટેકમાં વિગતો નીચે મજબ છે.

स्थावर भिलंडतमा जराहा मा	८ लघ स्वरमा आस्र्य मग	विवामा आव छ, ४ना टूडमा विगता	નાય મુજબ છ.				
ઉદ્યારકર્તાઓ, અને	ડિમાન્ડ નોટિસ તારીખ,	મિલકતનું પરિશિ	ര (ഗി)				
સહ-ઉદ્યારકર્તાઓ, અને	રકમ અને	ગુજરાત રાજ્ય ના રજીસ્ટ્રેશન ડિા	સ્ટ્રેક્ટ અમદાવાદ ના સબ-				
જમીનદારો ના નામ (એ) લોન ખાતા નંબર (સી)		iai नंબर (सी) रहारद्रेशन डिस्ट्रिड्ट અમદાવાદ ના અમદાવાદ ताલુકાના મોર્જ नी सिम ना रेवेन्य सर्वे नंબर ५६७/९ ना टी.पी . नंબर					
૧. ઉદ્યારકર્તા :- ધર્મેશ પંચાલ ૨. સહ-ઉદ્યારકર્તા :-	Dt. 03/08/2022 & Rs.27,34,142/- &	– ના ાતન ના રવેન્યું તેને નખર વર્ડિંગુમ ના ટા.પા . નખર ૨૮ ના ફાઇનલ પ્લોટ નંબર 33૯ ના સબ પ્લોટ નંબર ૧ અને ૪ વાળી બિન ખેતી ની જમીન પૈકી રહેણાંક હેતુ માટે તથા તેમાં આવેલા					
હેમા પંચાલ	A/C No.	બાંધકામ સહીત ની મિલકત કે જે ન્યૂ પાવાપુરી એપાર્ટમેન્ટ જે					
3. ધર્મેશ પંચાલ સહ-ઉધારકર્તા (સ્વ. જશોદાબેન પંચાલના કાયદેસરના વારસદાર) ૪. વર્ષાબેન મહેશચંદ્ર પંચાલ સહ (સ્વ. જશોદાબેન પંચાલના કા ૫. દિપ્તી હીરેન્દ્રકુમાર પંચાલ સહ (સ્વ. જશોદાબેન પંચાલના કા	& GJ/AMD/NRDA/A00000038 -ઉદ્યારકર્તા ચદેસરના વારસદાર) :-ઉદ્યારકર્તા	98 ન્યૂ પાવાપુરી કો. ઓપ. હાઉસિંગ સોસાચટી તરીકે ઓળખાય જેમાં ચોથા ફ્લોર ઉપર ફ્લેટ નંબર એફઓ/દ વાળી મિલક					
રિઝર્વ કિંમત (આર.પી) (ડી)	અર્નેસ્ટ મની ડિપોઝીટ (ઇએમડી) (આરપીના ૧૦%) (ઇ)	भिલકતના निरीक्षणनी तारीफ अने समय (એફ)	હરાજીની તારીખ અને ટેન્ડરો ખોલવાનો સમય (જી)				
31. 32.00.000/-	31. 3.20.000/-	તા. ૧૯-૦૨-૨૦૨૪ થી તા. ૨૪-૦૨-૨૦૨૪	તા. ૧૪-૦૩-૨૦૨૪				

(0.121 1.) (0.)	(301101) (311241011 1570) (3)	0101 21-14 (014)	300 21 3114141011 21314 (0)		
રૂા. 3૨,૦૦,૦૦૦/- (અંકે રૂા. બત્રીસ લાખ પુરા)	રૂા. 3,૨૦,૦૦૦/- (અંકે રૂા. ત્રણ લાખ વીસ હજાર પુરા)	તા. ૧૯-૦૨-૨૦૨૪ થી તા. ૨૪-૦૨-૨૦૨૪ સમચ : બપોરે ૧૨-૦૦ થી ૪-૦૦ સુધી	સમય : સવારે ૧૧-૦૦ થી ૪-૦૦ સુધી		
તથા, સિક્ચોર્ડ કેડિટર હિન્દુ કરવાનુ નક્કી કરેલ છે. વે	જા હાઉસીંગ ફાઇનાન્સ લિમિ ચાણની આ નોટિસ આજે	ટેડના અધિકૃત અધિકારીએ સદરહુ િ પ્રકાશિત થયેલ છે કે ઉપરની વિગ	સેક્ચોર્ડ અસ્કયામતનો નિકાલ તની સિક્ચોર્ડ અસ્ક્ચામતોનું		

૧૪-૦૩-૨૦૨૪ ના રોજ ઉપર જણાવેલ સમયે અને શિડયૂલ મુજબ હિન્દુજા હાઉસીંગ ફાઇનાન્સ લિમિટેડ, બ્રાન્ચ ઓફિસ : ત્રીજો માળ, ઈફ્ફકો ભવન, મારૂતિ કોમ્પલેસ પાછળ, પીન્દુ ગાર્મેન્ટ પાછળ, શીવરંજની રોડ પાસે, સેટેલાઈટ, અમદાવાદ-૩૮૦૦૧૫. ખાતે વેચાણ થશે. . ગિરવેદાર ખાસ નોટિસી અને જાહેર જનતાને સામાન્ય રીતે આથી ચેતવણી આપવામાં અને મનાઈ ફરમાવવામાં આવે છે કે સદર કાયદાના સેક્શન ૧૩(૧૩) ની શરતો મુજબ સદર સિક્ચોર્ડ અસ્કયામત સાથે કોઇ પણ રીતે વ્યવહાર કરવો નહીં અને આવો કોઈ પણ વ્યવહાર હિન્દુજા હાઉસીંગ ફાઇનાન્સ લિમિટેડના રકમો અને આગળના વ્યાજ સહિત થતા ચાર્જને આધીન

રહેશે. ગિરવેદારો ખાસ નોટિસોને **૧૩-૦૩-૨૦૨૪** (તારીખ) ના સાંજના ૫.૦૦ (સમય) અગાઉ ત્યાં સુધી થતા વ્યાજ સહિત તમામ લેણી રકમ ચૂકવી જવાની છેલ્લી તક આપવામાં આવે છે જેમાં કસૂર થયેથી સિક્ચોર્ડ અસ્ક્યામતનું શિડ્યૂલ મુજબ વેચાણ અહીં ઉપર કોલમ (ક)માં દર્શાવેલ સિક્ચોર્ડ અસ્કયામતની વિગતો નીચે સહી કરનારની શ્રેષ્ઠતમ જાણકારી અને જ્ઞાન મુજબ જણાવેલ છે, જેને આ વિગતોમાં કોઈ પણ ભૂલ, ગેરનિવેદન કે રહી ગયેલ હોય તે માટે જવાબદાર ગણાશે નહીં. ટેન્ડરર(રો)/ ઓફરર(રો) પ્રોસ્પેક્ટિવ બીડર(રો) / ખરીદદાર (રો)ને અત્રે સૂચિત કરવામાં આવે છે કે સિક્યોર્ડ અસ્ક્યામત સ્ટેચ્યુટરી ઓથોરિટીને ચૂકવવાપાત્ર કરભારણો અને દેણા (જો કોઈ હોય તો) તે સહિત વેચાશે અને તેમને વિનંતી કે પોતાના હિતમાં,

ટેન્ડરર(રો)/ઓફરર(રો) પ્રોસ્પેક્ટિવ બીડર(રો)/ ખરીદદાર(રો) એ પોતાની ઓફર કેવાયસી અને ઉપર જણાવેલ અર્નેસ્ટ મની ડિપોઝીટ (ઈએમડી) સાથે બંધ ક્વરમાં "મિલકતની ખરીદી માટે ઓફર" એમ ક્વર પર લખીને શાખા ઓફિસે ઉપર જણાવેલ હિન્દુજો હાઉસીંગ ફાઇનાન્સ લિમિટેડ, ત્રીજો માળ, ઈફફકો ભવને, મારૂતિ કોમ્પલેક્ષ પાછળ, પીન્ટુ ગાર્મેન્ટ પાછળ શીવરંજની ચાર રસ્તા પાસે, સેટેલાઈટ, અમદાવાદ–૩૮૦૦૧૫. (સરનામું) ખાતે **૧૩-૦૩-૨૦૨૪** ના રોજ સાંજના ૫.૦૦ પહેલા તાલું કર્યા પાર્ટિક કરાવવાના રહેશે. ઇએમડી રાષ્ટ્રીયકૃત /શેડચૂલ્ડ કોમર્શિયલ બેંકના "હિન્દુજા હાઉસીંગ ફાંઇનોન્સ લિમ્ટિડ" ની તરફેણમાં ચેન્નઇ ખાતે ચૂકવવાપાત્ર ડીડી /પીઓથી મીકલવી. નિરીક્ષણ, હરાજીની શરતો અને નિયમો, ટેન્ડર જમા કરાવવા સંદર્ભે કોઈ વધુ સ્પષ્ટીકરણ માટે મહેરબાની કરીને **સૌરભકુમાર નાપીત મો. હ૮७४૮૨૮૭૮૯ અને હીતેષકુમાર પટે**લ મો. હ૮હ૮હ૧હ૧હ૨ અને સુશીલ ચોંધરી મો. ૮૧૧૮૮૧૮૧૬૦ અને બન્ટી રામરખીયાણી મો. ૯૦૨૯૦૦૪હ૦૧ ઁ ૫૨ સંપર્ક કરવો. જે ટેન્ડરોની કંપની દ્વારા કટ ઓફ ટાઇમ પહેલા પૂરતી વિગતો સહિત ઓફિશ્યલ અને રિજસ્ટર્ડ રીતે જાણ કરાશે તેને હરાજી માટે ધ્યાને લેવાશે. અધિકૃત અધિકારી કોઈ પણ અથવા તમામ બીડ્સ કોઈ પણ કારણ આપ્યા વિના ૨૬ કરવાનો

સફળ બીડરે રિજસ્ટ્રેશન ફી, સ્ટેમ્પ ડચૂટી વગેરે જેવા કાયદેસર લાગુ પડતા ચાર્જેસ /કન્વેયન્સ માટે ચૂકવવાપાત્ર ફી વગેરે ભોગવવાના રહેશે. વેચાણનું સર્ટિફિકેટ ખરીદદાર/બીડરના નામે જ આપવામાં આવશે, અન્ય કોઈ નામથી નહીં. ખરીદદારે સ્ટેમ્પ ડયૂટી, રિજસ્ટ્રેશન ચાર્જેસ અને અન્ય તમામ સંલગ્ન ફીઝ, ડયૂટીઝ, ટેક્સ વગેરે વેચાણના સર્ટિફિકેટ સંદર્ભે થતા ખર્ચા ભોગવવાના રહેશે.

સફળ બીડર ખરીદદારે વેચાણ પ્રક્રિયા પર આવકવેરા, ૧૯૬૧ ના સેક્શન ૧૯૪(૧–એ) મુજબ ૧% ના દરે ટીડીએસ કાપવાનો રહેશે અને ફોર્મ રદ્દ ક્યુળી માં ચલન દર્શાવીને જમા કરાવવાનો રહેશે તથા ટીડીએસ સર્ટિફિકેટની અસલ રસીદ હિન્દુજા હાઉસીંગ ફાઇનાન્સ લિમિટેંડને (રૂ. ૫૦.૦૦ લાખ અને ઉપરની મિલક્ત) જમા કરાવવાની રહેશે. અધિકૃત અધિકારી કોઈ પણ અથવા તમામ બીડ્સ કોઈ પણ કારણ આપ્યા વિના ૨૬ કરવાનો અબાધિત અધિકાર રાખે છે.

અધિકૃત અધિકારી ક્થળ : અમદાવાદ તારીખ : ૧૦-૦૨-૨૦૨૪

પરિશિષ્ટ IV-એ,

સ્થાવર મિલકતના વેચાણ માટે સૂચના સિક્યોરીટી ઈન્ટેસ્ટ (એન્ફોર્સમેન્ટ) એક્ટ 2002ના નિયમ 8(6) અને નિયમ 9(1) મુજબ सिड्योरिटाઈडेशन એन्ड रिडन्स्ट्रड्शन ओइ इाઈनान्शियस એसेट्स એन्ड એन्ड्रोसेमेन्ट ओ:

સિક્યોરીટી ઈન્ટ્રેસ્ટ એક્ટ **2002** हેઠળ સ્થાવર મિલકતના વેચાણ માટે ઈ-ઓક્શન વેચાણ સૂચના. આ દ્વારા સામાન્ય જનતાને અને ખાસ કરીને કર્જદાર(રો) અને ગૅરટર(રો)ને સચના આપવામાં આવે છે કે, નીચે વર્ણન કરેલ સ્થાવર મિલકત કે જે **ઈન્ડિયાબુલ્સ હાઉસિંગ ફાઈનાન્સ લિ. [CIN**: L65922DL2005PLC136029] ("સીક્ચોર્ડ ક્રેડિટર") પાસે ગીરવે મુકેલ છે જેનો વાસ્તવિક કબજો સીક્યોર્ડ ક્રેડિટરના અધિકૃત અધિકારી દ્વારા લેવામાં આવ્યો છે તે રૂ. 30,93,275/- (રૂપિયા ત્રીસ લાખ ત્રાણું હજાર બસો પંચોતેર પૂરાં) ની વસૂલી માટે 29.02.2024 ના રોજ બપોરે 2.00 થી સાંજના 4.00 વાગ્યા દરમિયાન ''જેમ છે'' ''જયાં છે'', ''જેમ છે જે છે'' અને જે પણ જયાં છે દ્યોરણે વેચવામ આવશે, જે રમેશભાઈ સી. રંગાણી અને મિનાક્ષીબેન રમેશભાઈ રંગાણી પાસેથી લોન અકાઉન્ટ નં. HHLSUR00280938 માં બાકી નીકળતી મૂળ રેકમ, એરીઅર્સ (જમા થયેલા લેટ ચાર્જિસ સહિત) તે જ **05.02.2024** સુધીનાં વ્યાજ સહિત લોને એગ્રીમેન્ટ અને અન્ય સંબંધિત લોન દસ્તાવેજ(ર્જા)ની

સૂચિત પ્રોપર્ટીઓના ઓક્શન માટે અનામત કિંમત રૂ. 18,00,000/- (રૂપિયા અઢાર લાખ પૂરાં) છે. અને અર્નેસ્ટ મની કિપોઝિટ **(''ઇએમડી'') રૂ. 1,80,000/- (રૂપિયા એક લાખ એંસી હજાર પૂરાં)** એટલે અનામત મુલ્ય 10 % ના બરાબર રહેશે

શરતો મુજબ **06.02.2024** થી અમલી બને તેમ લાગુ ભાવિ વ્યાજ ઉપરાંત કાનૂની ખર્ચ અને અંન્ય

સ્થાવર મિલકત્તનું વર્ણન

મિલકત જે ઑપન પ્લૉટ નં. 296 અને વિસ્તાર 96.25 ચો. મીટર પાસિંગ પ્લાન અનસાર ધરાવે છે અને 34.64 ચો. મીટર રોડમાં જમીનનો અવિભાજિત હિસ્સો તેમ જ સીઓપી 14.73 ચો. મીટરમાં જમીનના અવિભાજિત हिસ્સા સहિત કુલ મળીને 145.62 ચો. મીટર ''સુંદરવન રેસિડેન્સીમાં' ધરાવે છે જે રેવેન્યૂ સર્વે નં. 88, બ્લૉક નં. 83, જેનો હેક્ટર વિસ્તાર 1-18-92 ચો. મીટર, આકાર 3.15.62 पैसा छे अने रेपेन्यू सर्पे नं. 89, ज्लॉड नं. 84, क्षेनो हेड्टर पिस्तार 1-66-48 थो. મીટર, આકાર રૂ. 21.94 પૈસા અને રેવેન્યૂ સર્વે નં. 90, બ્લૉક નં. 85, જેના હેક્ટર વિસ્તાર 0-68-97 ચો. મીટર, આકાર રૂ. 8.75 પૈસા છે, એકીકરણ પશ્ચાત નવો બ્લૉક નં. 83 જેનો હેક્ટર વિસ્તાર 3-54-37 ચો. મીટર હોવા સાથે મૌજે ગામ નાસદ, તાલુકા કામરેજ, જિલ્લો સુરત - 394180, ગુજરાત ખાતે છે.

પૂર્વમાં : સંલગ્ન પ્લૉટ નં. 321, 322. પશ્ચિમમાં : સંલગ્ન સોસાયટીનો આંતરિક રસ્તો. ઉत्तरभां : संसञ्ज प्लॉट नं. 297. દક્ષિણમાં : સંલગ્ન સોસાયટીની સીમા

યાર્જિસ સહિત સીક્યોર્ડ ક્રેડિટર્સને ચૂકવવાના બાકી નીકળે છે.

કૃપા કરીને વેચાણના વિગતસર નિચમો અને શરતો માટે સલામત લેણદાર ની વેબસાઈટ એટલે લિંક ıns.com નો સંદર્ભ લો. અને બિડિંગ માટે www.auctio

તારીખ : 06.02.2024 સ્થળ : સુરત

અધિકૃત અધિકારી ઈન્ડિયાબુલ્સ હાઉસિંગ ફાયનોન્સ લિમિટેડ

ફોર્મ નંબર યુઆરસી - ૨

ત્રધિનિયમના પ્રકરણ **ર૧** ના ભાગ **૧** હેઠળ નોંધણી વિશે સૂચના આપતી જાહેરાત **દ**કંપની અધિનિયમ, ર૦૧૩ ની કલમ ૩૭૪(બી) અને કંપની (નોંધણી કરવા માટે અધિકૃત) નિયમો, ૨૦૧૪ ના નિયમ ૪(૧) ને અનુસરીને

ı. આથી કંપની અધિનિયમ**, ૨૦૧**૩ ની કલમ **૩૬૬** ની પેટા-કલમ (૨) ના અનુસંધાનમાં સુચના આપવામાં આવે છે કે, એરોક્ષ પેઈન્ટસ (અગાઉ એપોલો કોટિંગ ઇન્ડસ્ટ્રીઝ) [M/s. AROHX PAINTS (Formerly known as M/s. APOLLO COATING INDUSTRIES)] ભાગીદારી પેઢીએ સેન્ટ્રલ રજિસ્ટ્રેશન સેન્ટર (સીઆરસી), ઇન્ડિયન ઇન્સ્ટિટ્યૂટ ઑફ કોર્પોરેટ અફેર્સ (ઓઈઆઈસીએ), પ્લોટ નં. ૬, ૭, ૮, સેક્ટર ૫, આઈએમટી માનેસર, જિલ્લો ગુડગાંવ (હરિયાણા) ૧૨૨૦૫૦ ને અરજી કરેલ છે એ અન્વયે ભાગીદારી પેઢી કંપની અધિનિયમ, ૨૦૧૩ ના પ્રકરણ ૨૧ ના ભાગ ૧ હેઠળ શેર દ્વારા મર્યાદિત જવાબદારીવાળી કંપની તરીકે નોંધાઈ થઇ શકે છે. ર. કંપનીના મુખ્ય હેતુઓ નીચે મુજબ છે:

ભારતમાં અર્થવા અન્ય કોઈ જગ્યાએ તેલ આધારિત પેઇન્ટ, પાણી આધારિત પેઇન્ટ, મેલામાઇન પેઇન્ટ, મેટાલિક પેઇન્ટ્સ, પોલીયુરેથેન્સ બેઝ પેઇન્ટ્સ. આલ્કિડ બેઝ પેઇન્ટ્સ, એનસી બેઝ પેઇન્ટ્સ, એન્ટી-કોરોસિવ પેઇન્ટ્સ, સ્ટોવિંગ પેઇન્ટ્સ, પાણી-આધારિત શાહી, ડિસ્ટેમ્પર્સ, પ્રાઇમર્સ, ઓક્સાઇડ, રેઝિન, એડહેસિવ, વાર્નિશ, થિનર, સ્પિરિટ, સ્ટ્રેનર, ઇમ્યુલેશન, કોર્ટિંગ્સ, પિગમેન્ટ્સ, ડાયઝ, દંતવલ્ક, પોલિશ, વોટર પૂર્ફિંગ પેઇન્ટ અને રસાયણો, બંધન તત્વો, પુટી, વોશર, બ્રશ અને કન્ટેનર અન્ય સેંલેંગ્ન રસાયણો, પેઇન્ટ, રંગ, કલર, સંયોજનો, મધ્યવર્તી, ઉપભોજ્ય પદાર્થી, પાવડર, પ્રવાહી ઘટકો, ઉત્પાદનો અને તેના ઉપ-ઉત્પાદનો વગેરેનું ઉત્પાદન, પ્રક્રિયા, રૂપાંતર, વ્યાપારીકરણ, રચના, સંયોજન, વિકાસ, શોધ, ગ્રેડેશન, સંશોધન, તૈયાર, પ્રોત્સાહન, પેક, પુનઃપેક, અર્ક, મિશ્રણ, પુરવઠો, આયાત, નિકાસ, ખરીદ, વેચાણ, વેપાર (જથ્થાબંધ હોય કે છૂટક) કરવું અને દલાલ, બ્રોકર, કન્સેશનર, સી એન્ડ એફ એજન્ટ, સ્ટોકીસ્ટ, ડિસ્ટ્રીબ્યુટર, સહયોગી, ટ્રાન્સપોર્ટર, સલાહકાર, જોબ વર્કર અથવા અન્ય રીતે તમામ પ્રકારોમાં વ્યવહાર કરવા.

તમામ પ્રકારના લાકડાના કોટિંગ્સ, વોલ કોટિંગ્સ, સિરામિક કોટિંગ્સ, રબર કોટિંગ, એન્ટિ-ગ્રેફિટી કોર્ટિંગ અને અન્ય તમામ પ્રકારના કોર્ટિંગ્સ, રેઝિન, રસાયણો, ફોર્મ્યુલેશનમાં ઉત્પાદન, ખરીદ, વેચાણ, આયાત, નિકાસ, ફેરફાર, રિપેક, ટ્રીટ એને અન્ય વ્યવહાર કરવો. દરેક પ્રકારના એબ્રેસીવ પેપર નું ઉત્પાદન, ખરીદ, વેચાણ, આયાત, નિકાસ, હેરફેર, પુનઃપેક, રીપેર અને તેને લગતા અન્ય તમામ પ્રકારના વ્યવહાર કરવા.

તમામ પ્રકારની ક્લરિંગ સામગ્રી, સપાટીના કોટિંગ્સ, લેકર્સ, સીલર્સ, ડાયઝ, ગમ, ગુંદર, લાકડાના ફિલ્ટર, અન્ય સપાટી સક્રિય એજન્ટો, ટેનિંગ એજન્ટ્સ, કોટિંગ્સ, ઓઇલ સોફ્ટનર્સ, સિન્થેટિક ફાઇબર્સ અને આને લગતી અન્ય તમામ વસ્તુનું ઉત્પાદન, ખેરીદ, વેચાણ, આયાત, નિકાસ, ફેરફાર, પુનઃપેક, રીપેર અને તેને લગતા અન્ય તમામ પ્રકારના વ્યવહાર કરવા.

 સૂચિત કંપનીના ડ્રાફ્ટ મેમોરેન્ડમ અને આર્ટિકલ્સ ઓફ એસોસિએશનની નકલ જી-૧૧૩૯, મેટોડા જીઓઈડીસી, ગામ. મેટોડા, તા. લોધીકા, જિ. રાજકોટ, ગુજરાત, ભારત ૩૬૦૦૨૧ ("રજીસ્ટર્ડ ઓફિસ") ખાતે તપાસી શકાસે.

૪ઁ. આથી સચના આપવામાં આવે છે કે આ નોટીસ પ્રકાશનની તારીખથી એકવીસ દિવસની અંદર આ અરજી સામે વાંધો ઉઠાવનાર કોઈપણ વ્યક્તિ પોતાનો વાંધો સેન્ટ્રલ રજિસ્ટ્રેશન સેન્ટર (સીઆરસી), ઇન્ડિયન ઇન્સ્ટિટ્યૂટ ઑફ કોર્પોરેટ અફેર્સ (ઓઈઆઈસીએ), પ્લોટ નં**. ૬**, ૭, ૮, સેક્ટર ૫, આઈએમેટી માનેસર, જિલ્લો ગુડગાંવ (હરિયાણા) ૧૨૨૦૫૦ ખાતેના રજિસ્ટ્રારને જણાવી દેવો અને તેની એક નંકલ કંપનીને તેની રજીસ્ટર્ડ ઓફિસ ખાતે મોકલવાની રહેશે.

તારીખ: ૧૦/૦૨/૨૦૨૪

સ્થળ: રાજકોટ

(અગાઉ એપોલો કોર્ટિંગ ઇન્ડસ્ટ્રીઝ) ૧. રાજેશભાઈ લવજીભાઇ વાછાણી ૨. હરેશ મગનલાલ વડાવિયા ૩. રસિકલાલ કાંતિલાલ કૈલા અરજદાર/ભાગીદાર

એરોક્ષ પેઈન્ટસ વતી

હિન્દુજા હાઉસિંગ ફાઇનાન્સ લિમિટેડ



Place: Kolkata Dated: 9th February, 2024

અબાંધિત અધિકાર રાખે છે.

Shristi Infrastructure Development Corporation Limited

Regd. Office: Plot No. X - 1, 2 & 3, Block-EP, Sector V, Salt Lake City, Kolkata-700 091

CIŇ - L65922WB1990PLC049541

Phone No.: (033) 4020 2020 / 4015 4646 E-mail: investor.relations@shristicorp.com, Website: www.shristicorp.com

EXTRACT OF UNAUDITED STANDALONE AND CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED 31ST DECEMBER, 2023

		STANDALONE					CONSOLIDATED						
SI.	Particulars		Quarter Ended		9 Month		Year Ended		Quarter Endec			hs Ended	Year Ended
No.		31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023	31.12.2023	30.09.2023	31.12.2022	31.12.2023	31.12.2022	31.03.2023
		Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited	Unaudited	Unaudited	Unaudited	Unaudited	Unaudited	Audited
1	Total Income from operations	2,065.11	1,545.30	1,747.77	5,235.17	4,227.69	5,205.63	6,094.80	4,260.76	5,478.29	14,674.55	18,307.00	22,575.45
2	Net Profit / (Loss) for the period (before Tax and Exceptional item)	(1,179.20)	(1,230.55)	(1,455.16)	(3,460.38)	(4,638.37)	(6,460.81)	(1,185.42)	(1,541.03)	(1,702.02)	(3,845.03)	(5,243.45)	(6,869.57)
3	Net Profit / (Loss) for the period before Tax (after Exceptional item)	(1,179.20)	(1,230.55)	(1,455.16)	(3,460.38)	(4,638.37)	(7,509.76)	(1,185.42)	(1,541.03)	(1,702.02)	(3,845.03)	(5,243.45)	(7,918.52)
4	Net Profit / (Loss) for the period after Tax (after Exceptional item)	(1,395.65)	(1,286.00)	(1,447.96)	(3,787.74)	(4,783.43)	(7,841.53)	(1,405.61)	(1,601.90)	(1,702.78)	(4,181.55)	(5,451.85)	(8,304.82)
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(1,395.92)	(1,286.28)	(1,446.87)	(3,788.55)	(4,780.17)	(7,842.58)	(1,907.60)	(2,120.66)	(2,209.85)	(5,621.90)	(6,691.92)	(9,784.98)
6	Paid up Equity Share Capital (Face value Rs. 10/-)	2,220.00	2,220.00	2,220.00	2,220.00	2,220.00	2,220.00	2,220.00	2,220.00	2,220.00	2,220.00	2,220.00	2,220.00
7	Reserves (excluding Revaluation Reserves as shown in the Audited Balance Sheet)	(8,849.03)	(7,453.10)	(1,761.58)	(8,849.03)	(1,761.58)	(5,060.48)	(28,745.26)	(26,849.36)	(18,736.27)	(28,745.26)	(18,736.27)	(23,123.36)
8	Net Worth	(6,629.03)	(5,233.10)	458.42	(6,629.03)	458.42	(2,840.48)	(26,525.26)	(24,629.36)	(16,516.27)	(26,525.26)	(16,516.27)	(20,903.36)
9	Paid up Debt Capital/ Outstanding Debt	45,916.63	46,991.16	56,084.88	45,916.63	56,084.88	49,499.82	102,792.35	103,855.14	114,134.90	102,792.35	114,134.90	106,374.45
10	Debt Equity Ratio	(6.93)	(8.98)	122.34	(6.93)	122.34	(17.43)	(3.88)	(4.22)	(6.91)	(3.88)	(6.91)	(5.09)
11	Earning per Share (of Rs 10/- each)												
	(i) Basic (Rs.)	(6.29)	(5.79)	(6.52)	(6.29)	(21.55)	(35.32)	(8.59)	(9.55)	(9.96)	(25.32)	(30.16)	(44.02)
	(ii) Diluted (Rs.)	(6.29)	(5.79)	(6.52)	(6.29)	(21.55)	(35.32)	(8.59)	(9.55)	(9.96)	(25.32)	(30.16)	(44.02)
12	Debenture Redemption Reserve	2,718.76	2,618.07	2,315.98	2,718.76	2,315.98	2,416.68	2,718.76	2,618.07	2,315.98	2,718.76	2,315.98	2,416.68
13	Debt Service Coverage Ratio	(0.21)	(0.19)	0.11	(0.17)	0.06	(0.13)	0.12	(0.05)	0.30	0.07	0.29	0.14
14	Interest Service Coverage Ratio	(0.50)	(0.53)	0.13	(0.43)	0.07	(0.16)	0.28	(0.14)	0.35	0.18	0.34	0.17

Note: 1. The above financial results have been reviewed by the Audit Committee and approved by the Board of Directors at their meeting held on 9th February, 2024. 2. The above is an extract of the detailed format of Quarterly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Quarterly Financial Results are available on the Stock Exchange website i.e BSE website (www.bseindia.com), Calcutta Stock Exchange Limited (www.cse-india.com) and Company's website

> For and on behalf of the Board of Directors Shristi Infrastructure Development Corporation Limited Sunil Jha Managing Director



(Rs. In lakhs except per share data)

31/12/2022 31/12/2023 31/12/2023 31/12/2022

Quarter

ended on

Consolidated (Unaudited)

Nine Months Quarter

ended on lended on



Particulars

Total income

Other Equity

Diluted

Net profit/ (loss) before tax

(Face value of INR 10 each)

Total Comprehensive Income/ (loss)

Net profit/ (loss) after tax

Equity Share Capital

Earnings per share

Aster DM Healthcare Limited

CIN: L85110KA2008PLC147259

Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India. Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

3,948.55

Annualised

8.54

8.53

Annualised

1.07

1.07

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

Standalone Nine Months ended Year ended Quarter ended Nine Months ended Year ended 31-Dec-231 31-Mar-23 31-Dec-22 31-Dec-23 31-Mar-23 31-Dec-23 | 31-Dec-22 30-Sep-23 31-Dec-22 (Unaudited) (Unaudited (Audited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Audited) 1,141.82 1,583.51 10,268.35 529.69 1,536.24 8,734.78 12,011.13 537.83 128.28 329.30 535.08 53.19 56.69 41.44 162.70 182.33 301.55 34.58 121.42 173.29 292.90 475.49 53.19 59.06 165.07 213.74 173.70 34.58 121.42 674.44 53.19 165.07 238.90 59.06 499.52 499.52 499.52 499.52 499.52 499.52 499.52 499.52 499.52

Annualised

1.19

1.19

Annualised

0.70

0.69

Annualised

3.32

3.31

◆The unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee on February 08, 2024 and approved by the Board of Directors at its meeting held on February 08, 2024.

Annualised

5.11

5.10

◆The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial statements is made available on the Company's website at www.asterdmhealthcare.com/investors and stock exchange website at BSE https://www.bseindia.com/ and NSE https://www.nseindia.com/.

◆The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

Annualised

3.08

3.08

Quarter ended

(Unaudited)

3,325.22

(5.16)

(15.33)

12.75

499.52

Annualised

(0.62)

(0.62)

31-Dec-22

(Unaudited)

3,200.67

173.44

159.03

191.59

499.52

Annualised

2.80

2.80

31-Dec-23 | 30-Sep-23

(Unaudited)

3,718.56

233.46

209.22

208.96

499.52

Annualised

3.60

3.60

Place: Dubai Date: February 08, 2024 For **Aster DM Healthcare Limited** Sd/-Alisha Moopen **Deputy Managing Director** DIN: 02432525

Annualised

2.44

2.44

2,631.04

Annualised

3.48

3.48

(Amount in INR crores except per share data)



Date: February 9, 2024

Place: Ahmedabad

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481

Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN: L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023

7 × 7	i i i i i i i i i i i i i i i i i i i	90	94 6	Rupees	in Million	5 10	
				Corresponding 3 Months ended	Year to date figures for the current	Year to date figures for the	
Sr. No.	Particulars	3 Months	Preceding 3	31/12/2022 in		previous	Previous year
		ended	Months ended	the previous	ended	period ended	ended
		31/12/2023	1.0	year	31/12/2023	37	31/03/2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	45,052	43,688	42,571	140,136	122,269	172,374
2	Net Profit for the period before exceptional items and tax	9,255	10,072	7,801	32,761	21,068	31,939
3	Net Profit for the period after exceptional items but before tax	9,255	10,072	7,801	32,619	21,039	25,897
4	Net Profit for the period from continuing operations	7,678	8,017	6,225	26,574	16,661	19,649
5	Profit/ [Loss] after tax from discontinued operations	218	(10)	4	198	(24)	(46)
6	Net Profit for the period after tax and Non-Controlling Interest	7,896	8,007	6,229	26,772	16,637	19,603
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	8,099	7,446	5,479	26,476	13,444	16,459
8	Paid-up equity share capital (Face value Re. 1/-)	1,012	1,012	1,012	1,012	1,012	1,012
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)						174,146
10	Earnings per share for continuing operations (not annualised for the quarter and nine months)						
a	Basic (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
b	Diluted (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)						
	Basic (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
	Diluted (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
Note:			12.	li d			

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

> By Order of the Board, For Zydus Lifesciences Limited,

> > (Rs. In lakhs)

Managing Director DIN: 00131995

Dr. Sharvil P. Patel



National Commodity & Derivatives Exchange Limited

CIN: U51909MH2003PLC140116

Regd Office: Akruti Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West, Mumbai, Maharashtra 400078

Ph: 022-66406789 | Email: askus@ncdex.com | Website: www.ncdex.com

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023

Standalone Consolidated Quarter Nine months Quarter Quarter Nine months Quarter SI. ended **Particulars** ended ended ended ended ended No. 31.12.2023 31.12.2023 31.12.2022 31.12.2023 31.12.2022 31.12.2023 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) Total Income from operations 1,210 1,167 4,133 3,313 3,430 10,209 2. Net profit/ (Loss) for the period (before Tax, Exceptional (1,438)(1,415)(3,619)(1,311)(1,512)(3,275)and/or Extraordinary items#) Net profit/ (Loss) for the period before Tax (after 3. 1,268 (1,415)(323)(1,311)(1,548)(3,231)Exceptional and/or Extraordinary items#) Net profit/ (Loss) for the period after Tax (after 1,488 (1,045)321 (2,497)(1,126)(1,113)Exceptional and/or Extraordinary items#) lotal Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other 1,521 (1,065)357 (1,107)(1,164)(2,505)Comprehensive Income (after tax)] **Equity Share Capital** 5,068 5,068 5,068 5,068 5,068 5,068 Reserves (excluding Revaluation Reserve) as shown in 7. Audited Balance Sheet of the previous year Earnings Per Share (FV ₹ 10 each) (for continuing and 8. discontinued operations) 2.94 (2.06)0.63 (2.15)(2.11)(4.69)1. Basic (₹): Not annualised

Notes:

2. Diluted (₹): Not annualised

1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financials are available on our website www.ncdex.com

2.94

2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.

(2.06)

0.63

(2.15)

3 #(i) In standalone financial statements, during the quarter ended December 31,2023, the Exchange has received excess contribution of Rs.15 lakh and Rs. 590 lakh during the half year ended September 30,2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd.(NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31,2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment and the same is credited to the statement of profit and loss and shown as an Exceptional item.

(ii) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has sold 8.71% (31 lakh equity share) of its stake in its subsidiary, NCDEX e-Markets Limited (NeML), to its wholly owned subsidiary, NCCL, for a consideration of Rs. 3,000.80 lakh. The profit earned on the said stake sale of Rs. 2,691 lakh has been credited to the statement of profit and loss and shown as an exceptional item.

(iii) In case of subsidiary NCDEX e Markets Limited (NeML), NeML has incurred expenses of Rs. 36 Lakhs on newly incorporated Joint Venture during the nine months ended December 31, 2022. As the approval for commencement of business is awaited from the relevant authority, the said expenses have been shown as an exceptional item. (iv) In case of subsidiary NCDEX e Markets Limited (NeML), during the nine months ended December 31, 2023, exceptional Income of Rs 44 lakh is on account of income

booked for recovery of Preincorporation and other expenses incurred on behalf of newly incorporated JV, prior to receipt of approval from Regulatory authorities.

For and on behalf of the Board of Directors

(2.11)

(4.69)

BENGALURU

Place: Mumbai Date: February 9, 2024

Arun Raste Managing Director & Chief Executive Officer DIN - 08561128 **CONCORD BIOTECH LIMITED**

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat Phone No.: +91-79-68138700 || Fax: +91-79-68138725 || CIN: L24230GJ1984PLC007440 Email Id : complianceofficer@concordbiotech.com || Website : www. concordbiotech.com Regd. Office & Plant: 1482-86, Trasad Road, Dholka, District: Ahmedabad - 382225, Gujarat, India Phone No.: +91-2714-222604, 398200 || Fax: +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

Standalone (Unaudited)

Nine Months

ended on

31/12/2023

Quarter

ended on

Quarter

ended on

31/12/2023

Particulars

1	Total Income from Operations	24,079.65	69,796.98	24,068.29	24,079.65	69,796.98	24,068.29
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,455.30	20,751.75	7,907.55	7,757.27	21,308.69	7,736.83
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(64.87)	(40.36)	17.94	(64.87)	(40.36)	17.94
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.		1,28,151.88	5		1,28,151.88	
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations - Not Annualised)						
	1) Basic	7.13	19.84	7.56	7,41	20.37	7.40
	2) Diluted	7.13	19.84	7.56	7.41	20.37	7.40

Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly / Nine Months Standalone and

(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules /AS Rules, whichever is applicable.

(c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 08, 2024.

For and on behalf of board of directors of Concord Biotech Limited **Ankur Vaid**

Place: Ahmedabad Date: Fennruary 8, 2024 Joint Managing Director & CEO - DIN: 01857225

PSP

PSP Projects Limited

Consolidated

CIN:L45201GJ2008PLC054868

Registered Office: PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058 Website: www.pspprojects.com

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023 (₹ in Lakhs)

- 1	[6	Concentation						
		Quarte	Nine Months Ended					
Sr. No.	Particular	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)				
1.	Total Income from Operations	71,118.31	50,659.07	1,85,617.46				
2.	Net Profit for the period (before Tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	4,204.40	4,824.99	14,468.84				
3.	Net Profit for the period (after tax, Exceptional and Extraordinary Items before Share of Profit/(Loss) from Joint Venture)	3,106.66	3,532.82	10,737.75				
4.	Net Profit for the period (after tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	3,108.32	3,536.01	10,745.06				
5.	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	3,110.62	3,538.31	10,751.96				
6.	Paid-up Equity Share Capital - Face Value ₹10/- each	3,600.00	3,600.00	3,600.00				
7.	Other Equity excluding Revaluation Reserves							
8.	Earnings Per Share of ₹ 10/-each (in ₹) (Not Annualised)			V. 107 T. 104 40.				
	Basic	8.63	9.82	29.85				
	Diluted	8.63	9.82	29.85				

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09, 2024. (₹ in Lakhs) 2. Additional information on Unaudited Standalone Financial Results are as follows:

Standalone Quarter Ended Nine Months Ended 31.12.2023 31.12.2022 31.12.2023 Particular (Unaudited) (Unaudited) (Unaudited) 69,661.92 49,739.28 1,81,332.80 Revenue from Operations Profit/(Loss) before tax and Exceptional item 4,397.86 4,815.39 14,636.12

The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: www.pspprojects.com) For and on behalf of Board of Directors of PSP Projects Limited

> Prahaladbhai S. Patel Chairman, Managing Director & CEO

3,529.50

10,864.77

DIN: 00037633

FINANCE LIMITED Partnership for Prosperity

Place : Ahmedabad

Date: February 9, 2024

Profit/(Loss) after tax and Exceptional item

CIN:U65929MH1990PLC057829 Regd.Office: AVINISHA TOWER, MEHADIA CHOWK. DHANTOLI, NAGPUR - 440 012. Ph no.0712-6663999 Website: www.berarfinance.com E-mail: investor.relations@berarfinance.com

3,251.85

Extract of Financial Results for the quarter ended December 31, 2023 [Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)] (₹ in Lakhs, except per equity share data and Debt Equity Ratio

Quarter ended Quarter ended Year ended PARTICULARS Dec. 31, 2023 Dec. 31, 2022 March 31,2023 UNAUDITED UNAUDITED AUDITED Total Income from Operations 6662.90 6259.69 21788.93 Net Profit/(Loss) for the period (before Tax, Exceptional 741.10 1000.83 2172.78 and/or Extraordinary items #) Net Profit/(Loss) for the period before tax (after Exceptional 741.10 1000.83 2172.78 and/or Extraordinary items #) 517.58 Net Profit /(Loss)for the period after tax (after Exceptional and/or Extraordinary items#) Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive 522.11 897.90 1709.27 Income (after tax)] 1233.68 1233.68 1233.68 Paid -up Equity Share Capital Reserves (excluding Revaluation Reserve) 11895.60 10345.60 11895.60 Securities Premium Account 14123.94 14123.94 14123.94 Net worth (Including Retained earnings and ESOP) 29113.77 27579.63 27523.60 10 Paid up Debt Capital/ Outstanding Debt 92679.81 85014.88 83190.22 11 Outstanding Redeemable Preference Shares NA NA. NA 12 Debt Equity Ratio 3.18 3.08 3.02 13 Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)* 4.20 7.2413.85 7.24 b) Diluted 13.79 4.18 14 Capital Redemption Reserve NA NA NA NA NA 15 Debenture Redemption Reserve NA 16 Debt Service Coverage Ratio NA NA NA 17 Interest Service Coverage Ratio NA

Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind AS Rules.

Not annualised for quarter ended December 31, 2023 and December 31, 2022.

/CIR/2022/0000000103 dated July 29, 2022 as amended ("Circular").

a) The above Results have been reviewed by the Audit Committee and subsequently approved by the Board of

Directors at their respective meetings held on February 09, 2024. b) The above is an extract of the detailed format of financial results filed with the BSE Limited ("Stock Exchange")

under Regulation 52 of the SEBI Listing Regulations. The full format of the financial results is available on the website of the Stock Exchange i.e www.bseindia.com and on the website of the Company i.e c) For the other line items referred in regulation 52 (4) of the SEBI Listing Regulations, pertinent disclosures have

been made to BSE Limited and can be accessed on www.bseindia.com. and on the website of the Company i.e. www.berarfinance.com This Extract of Financial Results has been prepared in accordance with the requirement of Regulation 52 of the

SEBI Listing Regulations read with Operational Circular bearing reference no. SEBI /HO /DDHS /DDHS Div1 /P

For and on behalf of Board of Directors of Berar Finance Limited

(Sandeep Jawanjal) Place: Nagpur Managing Director Date: February 09, 2024 DIN: 01490054

financialexp.epapr.in

WWW.FINANCIALEXPRESS.COM



Aster DM Healthcare Limited

CIN: L85110KA2008PLC147259 Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India. Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE OUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(Amount in INR crores except per share data)

	f		Conso	lidated					Stand	dalone		
Particulars		Quarter ende	d	Nine Mor	iths ended	Year ended		Quarter ende	d	Nine Mor	nths ended	Year ended
	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total income	3,718.56	3,325.22	3,200.67	10,268.35	8,734.78	12,011.13	537.83	529.69	409.33	1,536.24	1,141.82	1,583.51
Net profit/ (loss) before tax	233.46	(5.16)	173.44	301.55	329.30	535.08	53.19	56.69	41.44	162.70	128.28	182.33
Net profit/ (loss) after tax	209.22	(15.33)	159.03	213.74		475.49		59.06	34.58	165.07	121.42	173.29
Total Comprehensive Income/ (loss)	208.96	12.75	191.59	238.90	466.88	674.44	53.19	59.06	34.58	165.07	121.42	173.70
Equity Share Capital	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52
Other Equity	-	- 1	- 1	- [-	3,948.55	-	- 1	- 1	- 1	-	2,631.04
Earnings per share (Face value of INR 10 each)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised
Basic	3.60	(0.62)	2.80	3.08	5.11	8.54	1.07	1.19	0.70	3.32	2.44	3.48
Diluted	3.60	(0.62)	2.80	3.08	5.10	8.53	1.07	1.19	0.69	3.31	2.44	3.48

- The unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee on February 08, 2024 and approved by the Board of Directors at its meeting held on February 08, 2024.
- The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial statements is made available on the Company's website at www.asterdmhealthcare.com/investors and stock exchange website at BSE https://www.bseindia.com/ and NSE https://www.nseindia.com/.
- ◆The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

For Aster DM Healthcare Limited

Alisha Moopen **Deputy Managing Director**

DIN: 02432525

Place: Dubai Date: February 08, 2024

Dedicated To Life

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481 Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN: L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023 Rupees in Million

				.tupees			
	l s		7	Corresponding	Year to date	10	
				3 Months	figures for	Year to date	
Sr. No	Particulars			ended		figures for the	
		3 Months		31/12/2022 in	period	previous	Previous year
		ended	Months ended		ended	period ended	ended
		31/12/2023		year	31/12/2023		31/03/2023
		(Unaudited)	127	(Unaudited)	0	- 2	(Audited)
1	Total income from operations	45,052	43,688	42,571	140,136	122,269	172,374
2	Net Profit for the period before exceptional items and tax	9,255	10,072	7,801	32,761	21,068	31,939
3	Net Profit for the period after exceptional items but before tax	9,255	10,072	7,801	32,619	21,039	25,897
4	Net Profit for the period from continuing operations	7,678	8,017	6,225	26,574	16,661	19,649
5	Profit/ [Loss] after tax from discontinued operations	218	(10)	4	198	(24)	(46)
6	Net Profit for the period after tax and Non-Controlling Interest	7,896	8,007	6,229	26,772	16,637	19,603
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	8,099	7,446	5,479	26,476	13,444	16,459
8	Paid-up equity share capital (Face value Re. 1/-)	1,012	1,012	1,012	1,012	1,012	1,012
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)						174,146
10	Earnings per share for continuing operations (not annualised for the quarter and nine months)						
a	Basic (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
b	Diluted (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)						
a	Basic (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
b	Diluted (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
Note:		100	25		2 2	3.0	

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel Managing Director DIN: 00131995

Date: February 9, 2024 Place: Ahmedabad



National Commodity & Derivatives Exchange Limited CIN: U51909MH2003PLC140116

Regd Office: Akruti Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West, Mumbai, Maharashtra 400078

Ph: 022-66406789 | Email: askus@ncdex.com | Website: www.ncdex.com

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023

(Rs. In lakhs) Consolidated

		o e	Standalone			Consolidated	
SI. No.	Particulars	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023
	99	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1.	Total Income from operations	1,210	1,167	4,133	3,313	3,430	10,209
2.	Net profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	(1,438)	(1,415)	(3,619)	(1,311)	(1,512)	(3,275)
3.	Net profit/ (Loss) for the period before Tax (after Exceptional and/or Extraordinary items#)	1,268	(1,415)	(323)	(1,311)	(1,548)	(3,231)
4.	Net profit/ (Loss) for the period after Tax (after Exceptional and/or Extraordinary items#)	1,488	(1,045)	321	(1,126)	(1,113)	(2,497)
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	1,521	(1,065)	357	(1,107)	(1,164)	(2,505)
6.	Equity Share Capital	5,068	5,068	5,068	5,068	5,068	5,068
7.	Reserves (excluding Revaluation Reserve) as shown in Audited Balance Sheet of the previous year	-	-	-	-	-	-
8.	Earnings Per Share (FV ₹ 10 each) (for continuing and discontinued operations) 1. Basic (₹): Not annualised 2. Diluted (₹): Not annualised	2.94 2.94	(2.06) (2.06)	0.63 0.63	(2.15) (2.15)	(2.11) (2.11)	(4.69) (4.69)

- Notes:
- 1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financials are available on our website www.ncdex.com
- 2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.
- 3 #(i) In standalone financial statements, during the guarter ended December 31,2023, the Exchange has received excess contribution of Rs.15 lakh and Rs. 590 lakh during the half year ended September 30,2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd.(NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31,2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment and the same is credited to the statement of profit and loss and shown as an Exceptional item.

(ii) In standalone financial statements, during the guarter ended December 31, 2023, the Exchange has sold 8.71% (31 lakh equity share) of its stake in its subsidiary, NCDEX e-Markets Limited (NeML), to its wholly owned subsidiary, NCCL, for a consideration of Rs. 3,000.80 lakh. The profit earned on the said stake sale of Rs. 2,691 lakh has been credited to the statement of profit and loss and shown as an exceptional item.

(iii) In case of subsidiary NCDEX e Markets Limited (NeML), NeML has incurred expenses of Rs. 36 Lakhs on newly incorporated Joint Venture during the nine months ended December 31, 2022. As the approval for commencement of business is awaited from the relevant authority, the said expenses have been shown as an exceptional item.

(iv) In case of subsidiary NCDEX e Markets Limited (NeML), during the nine months ended December 31, 2023, exceptional Income of Rs 44 lakh is on account of income booked for recovery of Preincorporation and other expenses incurred on behalf of newly incorporated JV, prior to receipt of approval from Regulatory authorities.

For and on behalf of the Board of Directors

Arun Raste

Managing Director & Chief Executive Officer DIN - 08561128

CONCORD BIOTECH LIMITED B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat

Phone No.: +91-79-68138700 || Fax: +91-79-68138725 || CIN: L24230GJ1984PLC007440 Email Id: complianceofficer@concordbiotech.com | Website: www. concordbiotech.com Regd. Office & Plant: 1482-86, Trasad Road, Dholka, District: Ahmedabad - 382225, Gujarat, India Phone No.: +91-2714-222604, 398200 || Fax: +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

Ī.	200	0.0		(Rs. In I	akhs excep	ot per sha	re data)
П		Standal	one (Unaud	ited)	Consoli	dated (Una	udited)
SI. No	Particulars	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022
1.	Total Income from Operations	24,079.65	69,796.98	24,068.29	24,079.65	69,796.98	24,068.29
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,455.30	20,751.75	7,907.55	7,757.27	21,308.69	7,736.83
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(64.87)	(40.36)	17.94	(64.87)	(40.36)	17.94
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.		1,28,151.88		An	1,28,151.88	
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations - Not Annualised)		200	8		0	0
	1) Basic	7.13	19.84	7.56	7.41	20.37	7.40

Notes: (a) The above is an extract of the detailed format of Unaudited Quarterly / Nine Months Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com (b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with

19.84

7.41

(₹ in Lakhs)

7.13

Ind-AS Rules /AS Rules, whichever is applicable. (c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee

and approved by the Board of Directors of the Company at their meeting held on February 08, 2024. For and on behalf of board of directors of Concord Biotech Limited

Place: Ahmedabad Ankur Vaid Date: Fennruary 8, 2024 Joint Managing Director & CEO - DIN: 01857225

> **PSP Projects Limited** CIN:L45201GJ2008PLC054868

Registered Office: PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058 Website: www.pspprojects.com Extract of Unaudited Consolidated Financial Results for the Quarter and

Consolidated Nine Months Ended Quarter Ended

		- audito	Liidou	remo mondio Endod
Sr. No.	Particular		31.12.2022 (Unaudited)	31.12.2023 (Unaudited)
1.	Total Income from Operations	71,118.31	50,659.07	1,85,617.46
2.	Net Profit for the period (before Tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	4,204.40	4,824.99	14,468.84
3.	Net Profit for the period (after tax, Exceptional and Extraordinary Items before Share of Profit/(Loss) from Joint Venture)	3,106.66	3,532.82	10,737.75
4.	Net Profit for the period (after tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	3,108.32	3,536.01	10,745.06
5.	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	3,110.62	3,538.31	10,751.96
6.	Paid-up Equity Share Capital - Face Value ₹10/- each	3,600.00	3,600.00	3,600.00
7.	Other Equity excluding Revaluation Reserves	350	6970	85
8.	Earnings Per Share of ₹ 10/-each (in ₹) (Not Annualised)	14.04		
2000	Basic	8.63	9.82	29.85
	Diluted	8.63	9.82	29.85

Nine months ended December 31, 2023

2) Diluted

PSP

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09, 2024. (₹ in Lakhs) 2. Additional information on Unaudited Standalone Financial Results are as follows:

Standalone Quarter Ended Nine Months Ended 31.12.2023 31.12.2022 31.12.2023 Particular (Unaudited) (Unaudited) (Unaudited) Revenue from Operations 69,661.92 49,739.28 1,81,332.80 Profit/(Loss) before tax and Exceptional item 4,397.86 4,815.39 14,636.12 Profit/(Loss) after tax and Exceptional item 3,251.85 3,529.50 10,864.77

3. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: www.pspprojects.com) For and on behalf of Board of Directors of PSP Projects Limited

Prahaladbhai S. Patel Place: Ahmedabad Chairman, Managing Director & CEO Date: February 9, 2024 DIN: 00037633



Regd.Office: AVINISHA TOWER, MEHADIA CHOWK, DHANTOLI, NAGPUR - 440 012. Ph no.0712-6663999 Website: www.berarfinance.com E-mail: investor.relations@berarfinance.com

CIN:U65929MH1990PLC057829

[Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)] (₹ in Lakhs, except per equity share data and Debt Equity Ratio

Sr.	PARTICULARS	Quarter ended Dec. 31, 2023		Year ended March 31,2023
No.	*	UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations	6662.90	6259.69	21788.93
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
4	Net Profit /(Loss)for the period after tax (after Exceptional and/or Extraordinary items#)	517.58	892.62	1708.12
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	522.11	897.90	1709.27
6	Paid -up Equity Share Capital	1233.68	1233.68	1233.68
7	Reserves (excluding Revaluation Reserve)	11895.60	10345.60	11895.60
8	Securities Premium Account	14123.94	14123.94	14123.94
9	Net worth (Including Retained earnings and ESOP)	29113.77	27579.63	27523.60
10	Paid up Debt Capital/ Outstanding Debt	92679.81	85014.88	83190.22
11	Outstanding Redeemable Preference Shares	NA	NA	NA
12	Debt Equity Ratio	3.18	3.08	3.02
13	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)*			
- 1	a) Basic	4.20	7.24	13.85
	b) Diluted	4.18	7.24	13.79
14	Capital Redemption Reserve	NA	NA.	NA
15	Debenture Redemption Reserve	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA
17	Interest Service Coverage Ratio	NA.	NA	NA.

Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance

with Ind AS Rules. * Not annualised for quarter ended December 31, 2023 and December 31, 2022.

Place: Nagpur

a) The above Results have been reviewed by the Audit Committee and subsequently approved by the Board of

Directors at their respective meetings held on February 09, 2024. b) The above is an extract of the detailed format of financial results filed with the BSE Limited ("Stock Exchange") under Regulation 52 of the SEBI Listing Regulations. The full format of the financial results is available on the website of the Stock Exchange i.e www.bseindia.com and on the website of the Company i.e

www.berarfinance.com c) For the other line items referred in regulation 52 (4) of the SEBI Listing Regulations, pertinent disclosures have been made to BSE Limited and can be accessed on www.bseindia.com. and on the website of the Company i.e

d) This Extract of Financial Results has been prepared in accordance with the requirement of Regulation 52 of the SEBI Listing Regulations read with Operational Circular bearing reference no. SEBI /HO /DDHS /DDHS Div1 /P /CIR/2022/0000000103 dated July 29, 2022 as amended ("Circular").

Berar Finance Limited

For and on behalf of Board of Directors of

(Sandeep Jawanjal)

Chandigarh

Managing Director Date: February 09, 2024 DIN: 01490054

financialexp.epap.in

Place: Mumbai

Date: February 9, 2024

(Rs. In lakhs except per share data)

31/12/2022 31/12/2023 31/12/2023 31/12/2022

Quarter

ended on ended on

Consolidated (Unaudited)

Nine Months Quarter

ended on ended on



Aster DM Healthcare Limited

CIN: L85110KA2008PLC147259

Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India. Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(Amount in INR crores except per share data)

			Conso	lidated		77)			Stand	lalone		
Particulars		Quarter ende	d	Nine Mor	ths ended	Year ended		Quarter ende	d	Nine Mor	iths ended	Year ended
1	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total income	3,718.56	3,325.22	3,200.67	10,268.35	8,734.78	12,011.13	537.83	529.69	409.33	1,536.24	1,141.82	1,583.51
Net profit/ (loss) before tax	233.46	(5.16)	173.44	301.55	329.30	535.08	53.19	56.69	41.44	162.70	128.28	182.33
Net profit/ (loss) after tax	209.22	(15.33)	159.03	213.74	292.90	475.49	53.19	59.06	34.58	165.07	121.42	173.29
Total Comprehensive Income/ (loss)	208.96	12.75	191.59	238.90	466.88	674.44	53.19	59.06	34.58	165.07	121.42	173.70
Equity Share Capital	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52
Other Equity	-		- 8	- 8	-	3,948.55	78 - 8		- 3	- 7	-	2,631.04
Earnings per share (Face value of INR 10 each)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised
Basic	3.60	(0.62)	2.80	3.08	5.11	8.54	1.07	1.19	0.70	3.32	2.44	3.48
Diluted	3.60	(0.62)	2.80	3.08	5.10	8.53	1.07	1.19	0.69	3.31	2.44	3.48

The unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee on February 08, 2024 and approved by the Board of Directors at its meeting held on February 08, 2024.

◆The above is an extract of the detailed format of guarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial statements is made available on the Company's website at www.asterdmhealthcare.com/investors and stock exchange website at BSE https://www.bseindia.com/ and NSE https://www.nseindia.com/.

The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

For **Aster DM Healthcare Limited** Sd/-Alisha Moopen **Deputy Managing Director**

DIN: 02432525

Dedicated To Life

Date: February 9, 2024

Place: Ahmedabad

Date: February 08, 2024

Place: Dubai

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481

Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN: L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023

		90		Kupees	ii Million		
				Corresponding	Year to date		
				3 Months	figures for	Year to date	
Sr. No	Particulars			ended	the current	figures for the	
		3 Months	- 1	31/12/2022 in		previous	Previous year
		ended	Months ended		ended	period ended	ended
		31/12/2023	4.0	year	31/12/2023	33	31/03/2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	100	(Audited)
1	Total income from operations	45,052	43,688	42,571	140,136	122,269	172,374
2	Net Profit for the period before exceptional items and tax	9,255	10,072	7,801	32,761	21,068	31,939
3	Net Profit for the period after exceptional items but before tax	9,255	10,072	7,801	32,619	21,039	25,897
4	Net Profit for the period from continuing operations	7,678	8,017	6,225	26,574	16,661	19,649
5	Profit/ [Loss] after tax from discontinued operations	218	(10)	4	198	(24)	(46)
6	Net Profit for the period after tax and Non-Controlling Interest	7,896	8,007	6,229	26,772	16,637	19,603
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	8,099	7,446	5,479	26,476	13,444	16,459
8	Paid-up equity share capital (Face value Re. 1/-)	1,012	1,012	1,012	1,012	1,012	1,012
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)						174,146
10	Earnings per share for continuing operations (not annualised for the quarter and nine months)						- 1
a	Basic (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
l t	Diluted (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)						- 1
a	Basic (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
t	Diluted (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
Note	-						

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

> By Order of the Board, For Zydus Lifesciences Limited,

> > Dr. Sharvil P. Patel

Managing Director

DIN: 00131995



National Commodity & Derivatives Exchange Limited

CIN: U51909MH2003PLC140116

Regd Office: Akruti Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West, Mumbai. Maharashtra 400078

Ph: 022-66406789 | Email: askus@ncdex.com | Website: www.ncdex.com

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023 (Rs. In lakhs)

			Standalone	e.		Consolidated	
SI. No.	Particulars	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1.	Total Income from operations	1,210	1,167	4,133	3,313	3,430	10,209
2.	Net profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	(1,438)	(1,415)	(3,619)	(1,311)	(1,512)	(3,275)
3.	Net profit/ (Loss) for the period before Tax (after Exceptional and/or Extraordinary items#)	1,268	(1,415)	(323)	(1,311)	(1,548)	(3,231)
4.	Net profit/ (Loss) for the period after Tax (after Exceptional and/or Extraordinary items#)	1,488	(1,045)	321	(1,126)	(1,113)	(2,497)
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	1,521	(1,065)	357	(1,107)	(1,164)	(2,505)
6.	Equity Share Capital	5,068	5,068	5,068	5,068	5,068	5,068
7.	Reserves (excluding Revaluation Reserve) as shown in Audited Balance Sheet of the previous year		-	-	-	-	-
8.	Earnings Per Share (FV ₹ 10 each) (for continuing and discontinued operations) 1. Basic (₹): Not annualised 2. Diluted (₹): Not annualised	2.94 2.94	(2.06) (2.06)	0.63 0.63	(2.15) (2.15)	(2.11) (2.11)	(4.69) (4.69)

Notes:

- 1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financials are available on our website www.ncdex.com
- 2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.
- 3 #(i) In standalone financial statements, during the guarter ended December 31,2023, the Exchange has received excess contribution of Rs.15 lakh and Rs. 590 lakh during the half year ended September 30,2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd.(NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31,2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment and the same is credited to the statement of profit and loss and shown as an Exceptional item.

(ii) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has sold 8.71% (31 lakh equity share) of its stake in its subsidiary, NCDEX e-Markets Limited (NeML), to its wholly owned subsidiary, NCCL, for a consideration of Rs. 3,000.80 lakh. The profit earned on the said stake sale of Rs. 2,691 lakh has been credited to the statement of profit and loss and shown as an exceptional item.

(iii) In case of subsidiary NCDEX e Markets Limited (NeML), NeML has incurred expenses of Rs. 36 Lakhs on newly incorporated Joint Venture during the nine months ended December 31, 2022. As the approval for commencement of business is awaited from the relevant authority, the said expenses have been shown as an exceptional item. (iv) In case of subsidiary NCDEX e Markets Limited (NeML), during the nine months ended December 31, 2023, exceptional Income of Rs 44 lakh is on account of income

booked for recovery of Preincorporation and other expenses incurred on behalf of newly incorporated JV, prior to receipt of approval from Regulatory authorities.

For and on behalf of the Board of Directors

Place: Mumbai Date: February 9, 2024

Arun Raste Managing Director & Chief Executive Officer DIN - 08561128 **CONCORD BIOTECH LIMITED**

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat Phone No.: +91-79-68138700 || Fax: +91-79-68138725 || CIN: L24230GJ1984PLC007440 Email Id : complianceofficer@concordbiotech.com || Website : www. concordbiotech.com Regd. Office & Plant: 1482-86, Trasad Road, Dholka, District: Ahmedabad - 382225, Gujarat, India Phone No.: +91-2714-222604, 398200 || Fax: +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

Standalone (Unaudited)

31/12/2023 31/12/2023

ended on

Quarter

ended on

Nine Months Quarter

1	Total Income from Operations	24,079.65	69,796.98	24,068.29	24,079.65	69,796.98	24,068.29
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,455.30	20,751.75	7,907.55	7,757.27	21,308.69	7,736.83
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(64.87)	(40.36)	17.94	(64.87)	(40.36)	17.94
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.		1,28,151.88			1,28,151.88	
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations - Not Annualised)					8	
8	1) Basic	7.13	19.84	7.56	7.41	20.37	7.40
É	2) Diluted	7.13	19.84	7.56	7.41	20.37	7.40

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly / Nine Months Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com

(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules /AS Rules, whichever is applicable.

(c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 08, 2024.

For and on behalf of board of directors of Concord Biotech Limited **Ankur Vaid** Place: Ahmedabad

Date: Fennruary 8, 2024 Joint Managing Director & CEO - DIN: 01857225

PSP

Particulars

PSP Projects Limited

CIN:L45201GJ2008PLC054868

Registered Office: PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058 Website: www.pspprojects.com

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023 (₹ in Lakhs)

Consolidated Quarter Ended Nine Months Ended 31.12.2023 31.12.2022 31.12.2023 Particular No. (Unaudited) (Unaudited) (Unaudited) Total Income from Operations 71,118.31 50,659.07 1,85,617.46 Net Profit for the period (before Tax, Exceptional and Extraordinary 4,204.40 4,824.99 14,468.84 Items and Share of Profit/(Loss) from Joint Venture) Net Profit for the period (after tax, Exceptional and Extraordinary 3,106.66 3,532.82 10,737.75 Items before Share of Profit/(Loss) from Joint Venture) Net Profit for the period (after tax, Exceptional and Extraordinary 3,108.32 3,536.01 10,745.06 Items and Share of Profit/(Loss) from Joint Venture) Total Comprehensive Income for the period [Comprising Profit for 3,110.62 3,538.31 10,751.96 the period (after tax) and Other Comprehensive Income (after tax)) Paid-up Equity Share Capital - Face Value ₹10/- each 3,600.00 3,600.00 3,600.00 Other Equity excluding Revaluation Reserves Earnings Per Share of ₹ 10/-each (in ₹) (Not Annualised) 8.63 9.82 29.85 Diluted 8.63 9.82 29.85

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09, 2024. 2. Additional information on Unaudited Standalone Financial Results are as follows: (₹ in Lakhs)

Standalone Quarter Ended Nine Months Ended 31.12.2023 31.12.2022 31.12.2023 Particular (Unaudited) (Unaudited) (Unaudited) Revenue from Operations 69,661.92 49,739.28 1,81,332.80

Profit/(Loss) before tax and Exceptional item 4,397.86 4,815.39 14,636.12 Profit/(Loss) after tax and Exceptional item 3,251.85 3,529.50 10,864.77 3. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL: www.bseindia.com). National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: www.pspprojects.com) For and on behalf of Board of Directors

of PSP Projects Limited Prahaladbhai S. Patel Place: Ahmedabad Chairman, Managing Director & CEO Date: February 9, 2024 DIN: 00037633



Regd.Office: AVINISHA TOWER.MEHADIA CHOWK. DHANTOLI, NAGPUR - 440 012, Ph no.0712-6663999 Website: www.berarfinance.com E-mail: investor.relations@berarfinance.com

CIN:U65929MH1990PLC057829

Extract of Financial Results for the quarter ended December 31, 2023 [Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)]

(₹ in Lakhs, except per equity share data and Debt Equity Ratio)

Sr.	PARTICULARS	Quarter ended Dec. 31, 2023		Year ended March 31,2023
NO.		UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations	6662.90	6259.69	21788.93
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
4	Net Profit /(Loss)for the period after tax (after Exceptional and/or Extraordinary items#)	517.58	892.62	1708.12
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	522.11	897.90	1709.27
6	Paid -up Equity Share Capital	1233.68	1233.68	1233.68
7	Reserves (excluding Revaluation Reserve)	11895.60	10345.60	11895.60
8	Securities Premium Account	14123.94	14123.94	14123.94
9	Net worth (Including Retained earnings and ESOP)	29113.77	27579.63	27523.60
10	Paid up Debt Capital/ Outstanding Debt	92679.81	85014.88	83190.22
11	Outstanding Redeemable Preference Shares	NA	NA.	NA
12	Debt Equity Ratio	3.18	3.08	3.02
13	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)*	200,000	900330	25320
	a) Basic	4.20	7.24	13.85
	b) Diluted	4.18	7.24	13.79
	Capital Redemption Reserve	NA	NA	NA
	Debenture Redemption Reserve	NA	NA	NA
	Debt Service Coverage Ratio	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA

Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind AS Rules.

Not annualised for quarter ended December 31, 2023 and December 31, 2022.

/CIR/2022/0000000103 dated July 29, 2022 as amended ("Circular").

a) The above Results have been reviewed by the Audit Committee and subsequently approved by the Board of

Directors at their respective meetings held on February 09, 2024. b) The above is an extract of the detailed format of financial results filed with the BSE Limited ("Stock Exchange")

under Regulation 52 of the SEBI Listing Regulations. The full format of the financial results is available on the website of the Stock Exchange i.e www.bseindia.com and on the website of the Company i.e c) For the other line items referred in regulation 52 (4) of the SEBI Listing Regulations, pertinent disclosures have

been made to BSE Limited and can be accessed on www.bseindia.com. and on the website of the Company i.e www.berarfinance.com d) This Extract of Financial Results has been prepared in accordance with the requirement of Regulation 52 of the

SEBI Listing Regulations read with Operational Circular bearing reference no. SEBI /HO /DDHS /DDHS Div1 /P

For and on behalf of Board of Directors of Berar Finance Limited

(Sandeep Jawanjal) Place: Nagpur Managing Director Date: February 09, 2024 DIN: 01490054

financialexp.epapr.in CHENNAI/KOCHI

(Rs. In lakhs except per share data)



Aster DM Healthcare Limited

CIN: L85110KA2008PLC147259 Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India. Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(Amount in INR crores except per share data)

	1		Conso	lidated		.v	ec.		Stand	dalone		SV .
Particulars		Quarter ende	d	Nine Mor	nths ended	Year ended		Quarter ende	d	Nine Mor	nths ended	Year ended
	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total income	3,718.56	3,325.22	3,200.67	10,268.35	8,734.78	12,011.13	537.83	529.69	409.33	1,536.24	1,141.82	1,583.51
Net profit/ (loss) before tax	233.46	(5.16)	173.44	301.55	329.30	535.08	95	56.69	41.44	162.70	128.28	182.33
Net profit/ (loss) after tax	209.22	(15.33)	159.03	213.74	292.90	475.49	53.19	59.06	34.58	165.07	121.42	173.29
Total Comprehensive Income/ (loss)	208.96	12.75	191.59	238.90	466.88	674.44	53.19	59.06	34.58	165.07	121.42	173.70
Equity Share Capital	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52
Other Equity	- 1	· - 3	- 8	- 8	-	3,948.55	D - ?		- 8	- 8	-	2,631.04
Earnings per share (Face value of INR 10 each)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised
Basic	3.60	(0.62)	2.80	3.08	5.11	8.54	1.07	1.19	0.70	3.32	2.44	3.48
Diluted	3.60	(0.62)	2.80	3.08	5.10	8.53	1.07	1.19	0.69	3.31	2.44	3.48
◆The unaudited consolidated and standa	alone financia	results of the	Company fo	r the quarter	and nine mor	nths ended D	ecember 31.	2023 have be	en reviewed	by the Audit (Committee or	February 08

2024 and approved by the Board of Directors at its meeting held on February 08, 2024.

The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial statements is made available on the Company's website at www.asterdmhealthcare.com/investors and stock exchange website at BSE https://www.bseindia.com/ and NSE https://www.nseindia.com/.

◆The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

For Aster DM Healthcare Limited Sd/-Alisha Moopen **Deputy Managing Director**

DIN: 02432525

Dedicated To Life

Date: February 08, 2024

Place: Dubai

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481 Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023 Rupees in Million

CIN: L24230GJ1995PLC025878

				Corresponding	Year to date		
				3 Months	figures for	Year to date	_ I
Sr. N	Particulars			ended	the current	figures for the	
31.14	Fai ticulais	3 Months	Preceding 3	31/12/2022 in	period	previous	Previous year
		ended	Months ended	the previous	ended	period ended	
		31/12/2023	30/09/2023	year	31/12/2023	31/12/2022	31/03/2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	45,052	43,688	42,571	140,136	122,269	172,374
2	Net Profit for the period before exceptional items and tax	9,255	10,072	7,801	32,761	21,068	31,939
3	Net Profit for the period after exceptional items but before tax	9,255	10,072	7,801	32,619	21,039	25,897
4	Net Profit for the period from continuing operations	7,678	8,017	6,225	26,574	16,661	19,649
5	Profit/ [Loss] after tax from discontinued operations	218	(10)	4	198	(24)	(46)
6	Net Profit for the period after tax and Non-Controlling Interest	7,896	8,007	6,229	26,772	16,637	19,603
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	8,099	7,446	5,479	26,476	13,444	16,459
8	Paid-up equity share capital (Face value Re. 1/-)	1,012	1,012	1,012	1,012	1,012	1,012
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)						174,146
10	Earnings per share for continuing operations (not annualised for the quarter and nine months)						_ I
	Basic (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
	Diluted (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)						_ I
	Basic (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
	Diluted (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
Note	178						

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

By Order of the Board, For Zydus Lifesciences Limited,

> Dr. Sharvil P. Patel Managing Director DIN: 00131995

Place: Ahmedabad

Date: February 9, 2024



National Commodity & Derivatives Exchange Limited CIN: U51909MH2003PLC140116

Regd Office: Akruti Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West,

Standalone

Quarter

Nine months

Quarter

Mumbai, Maharashtra 400078

Ph: 022-66406789 Email: askus@ncdex.com Website: www.ncdex.com

Quarter

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023 (Rs. In lakhs)

ended ended ended ended ended **Particulars** ended 31.12.2023 31.12.2023 31.12.2022 31.12.2023 31.12.2022 31.12.2023 (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) (Unaudited) Total Income from operations 1,210 1,167 4,133 3,313 3,430 10,209 Net profit/ (Loss) for the period (before Tax, Exceptional (1,438)(1,415)(3,619)(1,311)(1,512)(3,275)and/or Extraordinary items#) Net profit/ (Loss) for the period before Tax (after (1,548)1,268 (1,415)(323)(1,311)(3,231)Exceptional and/or Extraordinary items#) Net profit/ (Loss) for the period after Tax (after 1,488 (1,045)321 (1,126)(1,113)(2,497)

2. 3. Exceptional and/or Extraordinary items#) Total Comprehensive Income for the period [Comprising 357 (2,505)1,521 (1,065)(1,107)(1,164)Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)] **Equity Share Capital** 6. 5,068 5,068 5,068 5,068 5,068 5,068 Reserves (excluding Revaluation Reserve) as shown in Audited Balance Sheet of the previous year Earnings Per Share (FV ₹ 10 each) (for continuing and 8. discontinued operations) 2.94 (2.06)0.63 (2.15)(2.11)(4.69)1. Basic (₹): Not annualised (4.69)2.94 (2.06)0.63 (2.15)(2.11)2. Diluted (₹): Not annualised

Notes:

Place: Mumbai

financialexp.epapr.in

Date: February 9, 2024

SI.

No.

1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financials are available on our website www.ncdex.com

2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.

3 #(i) In standalone financial statements, during the quarter ended December 31,2023, the Exchange has received excess contribution of Rs.15 lakh and Rs. 590 lakh during the half year ended September 30,2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd.(NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31,2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment and the same is credited to the statement of profit and loss and shown as an Exceptional item.

(ii) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has sold 8.71% (31 lakh equity share) of its stake in its subsidiary, NCDEX e-Markets Limited (NeML), to its wholly owned subsidiary, NCCL, for a consideration of Rs. 3,000.80 lakh. The profit earned on the said stake sale of Rs. 2,691 lakh has been credited to the statement of profit and loss and shown as an exceptional item.

(iii) In case of subsidiary NCDEX e Markets Limited (NeML), NeML has incurred expenses of Rs. 36 Lakhs on newly incorporated Joint Venture during the nine months ended December 31, 2022. As the approval for commencement of business is awaited from the relevant authority, the said expenses have been shown as an exceptional item.

(iv) In case of subsidiary NCDEX e Markets Limited (NeML), during the nine months ended December 31, 2023, exceptional Income of Rs 44 lakh is on account of income

booked for recovery of Preincorporation and other expenses incurred on behalf of newly incorporated JV, prior to receipt of approval from Regulatory authorities.

For and on behalf of the Board of Directors

Arun Raste

Managing Director & Chief Executive Officer DIN - 08561128

Consolidated

Quarter

Nine months

CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat Phone No.: +91-79-68138700 || Fax: +91-79-68138725 || CIN: L24230GJ1984PLC007440 Email Id: complianceofficer@concordbiotech.com | Website: www. concordbiotech.com Regd. Office & Plant: 1482-86, Trasad Road, Dholka, District: Ahmedabad - 382225, Gujarat, India Phone No.: +91-2714-222604, 398200 || Fax: +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

		Standal	one (Unaud	ited)	Consoli	dated (Una	udited)
SI. No	Particulars	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022
1	Total Income from Operations	24,079.65	69,796.98	24,068.29	24,079.65	69,796.98	24,068.29
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,455.30	20,751.75	7,907.55	7,757.27	21,308.69	7,736.83
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(64.87)	(40.36)	17.94	(64.87)	(40.36)	17.94
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.		1,28,151.88	5		1,28,151.88	
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations - Not Annualised)			,			
	1) Basic	7.13	19.84	7.56	7.41	20.37	7.40
	2) Diluted	7.13	19.84	7.56	7.41	20.37	7.40

Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com (b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with

Ind-AS Rules /AS Rules, whichever is applicable. (c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee

and approved by the Board of Directors of the Company at their meeting held on February 08, 2024. For and on behalf of board of directors of Concord Biotech Limited Place: Ahmedabad **Ankur Vaid**

Date: Fennruary 8, 2024 Joint Managing Director & CEO - DIN: 01857225

> **PSP Projects Limited** CIN:L45201GJ2008PLC054868

> > (₹ in Lakhs)

29.85

Registered Office: PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058 Website: www.pspprojects.com Extract of Unaudited Consolidated Financial Results for the Quarter and

Consolidated Quarter Ended Nine Months Ended 31.12.2023 31.12.2022 31.12.2023 Particular (Unaudited) (Unaudited) (Unaudited) No. 71,118.31 50,659.07 1,85,617.46 Total Income from Operations Net Profit for the period (before Tax, Exceptional and Extraordinary 4,204.40 4,824.99 14,468.84 Items and Share of Profit/(Loss) from Joint Venture) Net Profit for the period (after tax, Exceptional and Extraordinary 10,737.75 3,106.66 3,532.82 Items before Share of Profit/(Loss) from Joint Venture) Net Profit for the period (after tax, Exceptional and Extraordinary 3,108.32 3,536.01 10,745.06 Items and Share of Profit/(Loss) from Joint Venture) Total Comprehensive Income for the period [Comprising Profit for 3,110.62 3,538.31 10,751.96 the period (after tax) and Other Comprehensive Income (after tax)) 3,600.00 3,600.00 Paid-up Equity Share Capital - Face Value ₹10/- each 3,600.00 Other Equity excluding Revaluation Reserves Earnings Per Share of ₹10/-each (in ₹) (Not Annualised) Basic 8.63 9.82 29.85

Nine months ended December 31, 2023

Notes: 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their

respective meetings held on February 09, 2024. (₹ in Lakhs) 2. Additional information on Unaudited Standalone Financial Results are as follows:

Standalone Quarter Ended Nine Months Ended 31.12.2023 31.12.2022 31.12.2023 Particular (Unaudited) (Unaudited) (Unaudited) Revenue from Operations 69,661.92 49,739.28 1,81,332.80 Profit/(Loss) before tax and Exceptional item 4,397.86 4,815.39 14,636.12 Profit/(Loss) after tax and Exceptional item 3,251.85 3,529.50 10,864.77

3. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33

of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: www.pspprojects.com) For and on behalf of Board of Directors of PSP Projects Limited

Prahaladbhai S. Patel Place: Ahmedabad Chairman, Managing Director & CEO Date: February 9, 2024 DIN: 00037633



PSP

Diluted

Regd.Office: AVINISHA TOWER, MEHADIA CHOWK. DHANTOLI, NAGPUR - 440 012, Ph no.0712-6663999 Website: www.berarfinance.com E-mail: investor.relations@berarfinance.com

CIN:U65929MH1990PLC057829

8.63

9.82

[Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)] (₹ in Lakhs, except per equity share data and Debt Equity Ratio)

Quarter ended Quarter ended Year ended PARTICULARS Dec. 31, 2023 Dec. 31, 2022 March 31,2023 UNAUDITED UNAUDITED AUDITED Total Income from Operations 6662.90 6259.69 21788.93 Net Profit/(Loss) for the period (before Tax, Exceptional 741.10 1000.83 2172.78 and/or Extraordinary items #) Net Profit/(Loss) for the period before tax (after Exceptional 741.10 1000.83 2172.78 and/or Extraordinary items #) Net Profit /(Loss)for the period after tax (after Exceptional 517.58 1708.12 and/or Extraordinary items#) Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive 522.11 897.90 1709.27 Income (after tax)] 6 Paid -up Equity Share Capital 1233.68 1233.68 1233.68 Reserves (excluding Revaluation Reserve) 11895.60 10345.60 11895.60 Securities Premium Account 14123.94 14123.94 14123.94 Net worth (Including Retained earnings and ESOP) 29113.77 27579.63 27523.60 10 Paid up Debt Capital/ Outstanding Debt 92679.81 85014.88 83190.22 11 Outstanding Redeemable Preference Shares NA NA NA. 3.08 12 Debt Equity Ratio 3.18 3.02 13 Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)* 4.20 7.24 13.85 7.24 b) Diluted 4.18 13.79 14 Capital Redemption Reserve NA NA NA 15 Debenture Redemption Reserve NA NA NA 16 Debt Service Coverage Ratio NA NA NA 17 Interest Service Coverage Ratio NA

Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance

with Ind AS Rules. Not annualised for quarter ended December 31, 2023 and December 31, 2022.

a) The above Results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on February 09, 2024.

b) The above is an extract of the detailed format of financial results filed with the BSE Limited ("Stock Exchange") under Regulation 52 of the SEBI Listing Regulations. The full format of the financial results is available on the website of the Stock Exchange i.e www.bseindia.com and on the website of the Company i.e

c) For the other line items referred in regulation 52 (4) of the SEBI Listing Regulations, pertinent disclosures have been made to BSE Limited and can be accessed on www.bseindia.com. and on the website of the Company i.e.

This Extract of Financial Results has been prepared in accordance with the requirement of Regulation 52 of the SEBI Listing Regulations read with Operational Circular bearing reference no. SEBI /HO /DDHS /DDHS _Div1 /P /CIR/2022/0000000103 dated July 29, 2022 as amended ("Circular").

> For and on behalf of Board of Directors of Berar Finance Limited

> > (Sandeep Jawanjal) Managing Director DIN: 01490054

Date: February 09, 2024

New Delhi

Place: Nagpur





Aster DM Healthcare Limited

CIN: L85110KA2008PLC147259

Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India. Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

									(Amour	nt in INR cror	es except pe	r share data)
	a		Conso	lidated					Stan	dalone		
Particulars		Quarter ended Nine Months ended Year ende			Year ended	d Quarter ended			Nine Months ended		Year ended	
	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total income	3,718.56	3,325.22	3,200.67	10,268.35	8,734.78	12,011.13	537.83	529.69	409.33	1,536.24	1,141.82	1,583.51
Net profit/ (loss) before tax	233.46	(5.16)	173.44	301.55	329.30	535.08	53.19	56.69	41.44	162.70	128.28	182.33
Net profit/ (loss) after tax	209.22	(15.33)	159.03	213.74	292.90	475.49	53.19	59.06	34.58	165.07	121.42	173.29
Total Comprehensive Income/ (loss)	208.96	12.75	191.59	238.90	466.88	674.44	53.19	59.06	34.58	165.07	121.42	173.70
Equity Share Capital	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52
Other Equity	§ - 8	-	-	-	6 - V	3,948.55	-	-	g - 6	- 1	-	2,631.04
Earnings per share (Face value of INR 10 each)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised
Basic	3.60	(0.62)	2.80	3.08	5.11	8.54	1.07	1.19	0.70	3.32	2.44	3.48
Diluted	3.60	(0.62)	2.80	3.08	5.10	8.53	1.07	1.19	0.69	3.31	2.44	3.48

The unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee on February 08 2024 and approved by the Board of Directors at its meeting held on February 08, 2024.

◆The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial statements is made available on the Company's website at www.asterdmhealthcare.com/investors and stock exchange website at BSE https://www.bseindia.com/ and NSE https://www.nseindia.com/.

◆The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

Place: Dubai Date: February 08, 2024 For Aster DM Healthcare Limited Sd/-Alisha Moopen **Deputy Managing Director** DIN: 02432525



Dedicated To Life

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481 Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN: L24230GJ1995PLC025878 Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023

		ji		•	in Million		
l			& S	Corresponding	Year to date	9	66
l				3 Months	figures for	Year to date	
Sr. No.	Particulars			ended	the current	figures for the	
	1 41 41 41 41 41 41 41 41 41 41 41 41 41	3 Months	Preceding 3	31/12/2022 in		previous	Previous year
l		ended	Months ended	the previous	ended	period ended	ended
l		31/12/2023	V.	year	31/12/2023		31/03/2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	45,052	43,688	42,571	140,136	122,269	172,374
2	Net Profit for the period before exceptional items and tax	9,255	10,072	7,801	32,761	21,068	31,939
3	Net Profit for the period after exceptional items but before tax	9,255	10,072	7,801	32,619	21,039	25,897
4	Net Profit for the period from continuing operations	7,678	8,017	6,225	26,574	16,661	19,649
5	Profit/ [Loss] after tax from discontinued operations	218	(10)	4	198	(24)	(46)
6	Net Profit for the period after tax and Non-Controlling Interest	7,896	8,007	6,229	26,772	16,637	19,603
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	8,099	7,446	5,479	26,476	13,444	16,459
8	Paid-up equity share capital (Face value Re. 1/-)	1,012	1,012	1,012	1,012	1,012	1,012
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)						174,146
10	Earnings per share for continuing operations (not annualised for the quarter and nine months)						
a	Basic (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
b	Diluted (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)						
а	Basic (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
b	Diluted (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
Note:							

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

Bv Order of the Board, For Zydus Lifesciences Limited,

Date: February 9, 2024 Place: Ahmedabad

Dr. Sharvil P. Patel Managing Director DIN: 00131995



National Commodity & Derivatives Exchange Limited

CIN: U51909MH2003PLC140116

Regd Office: Akruti Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West, Mumbai, Maharashtra 400078

Ph: 022-66406789 | Email: askus@ncdex.com | Website: www.ncdex.com

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023 (Rs. In lakhs)

			Standalone			Consolidated	. 199
SI. No.	Particulars	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1.	Total Income from operations	1,210	1,167	4,133	3,313	3,430	10,209
2.	Net profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	(1,438)	(1,415)	(3,619)	(1,311)	(1,512)	(3,275)
3.	Net profit/ (Loss) for the period before Tax (after Exceptional and/or Extraordinary items#)	1,268	(1,415)	(323)	(1,311)	(1,548)	(3,231)
4.	Net profit/ (Loss) for the period after Tax (after Exceptional and/or Extraordinary items#)	1,488	(1,045)	321	(1,126)	(1,113)	(2,497)
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	1,521	(1,065)	357	(1,107)	(1,164)	(2,505)
6.	Equity Share Capital	5,068	5,068	5,068	5,068	5,068	5,068
7.	Reserves (excluding Revaluation Reserve) as shown in Audited Balance Sheet of the previous year	-	-	-	-	-	- 93
8.	Earnings Per Share (FV ₹ 10 each) (for continuing and discontinued operations) 1. Basic (₹): Not annualised 2. Diluted (₹): Not annualised	2.94 2.94	(2.06) (2.06)	0.63 0.63	(2.15) (2.15)	(2.11) (2.11)	(4.69) (4.69)

Place: Mumbai

Date: February 9, 2024

1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financials are available on our website www.ncdex.com

2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.

3 #(i) In standalone financial statements, during the guarter ended December 31,2023, the Exchange has received excess contribution of Rs.15 lakh and Rs. 590 lakh during the half year ended September 30,2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd.(NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31,2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment and the same is credited to the statement of profit and loss and shown as an Exceptional item.

(ii) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has sold 8.71% (31 lakh equity share) of its stake in its subsidiary, NCDEX e-Markets Limited (NeML), to its wholly owned subsidiary, NCCL, for a consideration of Rs. 3,000.80 lakh. The profit earned on the said stake sale of Rs. 2,691 lakh has been credited to the statement of profit and loss and shown as an exceptional item.

(iii) In case of subsidiary NCDEX e Markets Limited (NeML), NeML has incurred expenses of Rs. 36 Lakhs on newly incorporated Joint Venture during the nine months ended December 31, 2022. As the approval for commencement of business is awaited from the relevant authority, the said expenses have been shown as an exceptional item.

(iv) In case of subsidiary NCDEX e Markets Limited (NeML), during the nine months ended December 31, 2023, exceptional Income of Rs 44 lakh is on account of income booked for recovery of Preincorporation and other expenses incurred on behalf of newly incorporated JV, prior to receipt of approval from Regulatory authorities.

For and on behalf of the Board of Directors

Arun Raste Managing Director & Chief Executive Officer DIN - 08561128 **CONCORD BIOTECH LIMITED**

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat Phone No.: +91-79-68138700 || Fax: +91-79-68138725 || CIN: L24230GJ1984PLC007440 Email Id: complianceofficer@concordbiotech.com || Website: www.concordbiotech.com Regd. Office & Plant: 1482-86, Trasad Road, Dholka, District: Ahmedabad - 382225, Gujarat, India Phone No.: +91-2714-222604, 398200 || Fax: +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

100				(Rs. In la	akhs excep	ot per sha	re data)
		Standal	one (Unaud	ited)	Consoli	dated (Una	udited)
SI No	Particulars	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022
1	Total Income from Operations	24,079.65	69,796.98	24,068.29	24,079.65	69,796.98	24,068.29
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,455.30	20,751.75	7,907.55	7,757.27	21,308.69	7,736.83
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(64.87)	(40.36)	17.94	(64.87)	(40.36)	17.94
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	(2)	1,28,151.88			1,28,151.88	O.
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations - Not Annualised)	() ()					
	1) Basic	7.13	19.84	7.56	7,41	20.37	7.40
	2) Diluted	7.13	19.84	7.56	7.41	20.37	7.40

Notes: (a) The above is an extract of the detailed format of Unaudited Quarterly / Nine Months Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com

(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules /AS Rules, whichever is applicable.

(c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 08, 2024.

For and on behalf of board of directors of Concord Biotech Limited Place: Ahmedabad Ankur Vaid

Joint Managing Director & CEO - DIN: 01857225 Date: Fennruary 8, 2024



PSP Projects Limited

CIN:L45201GJ2008PLC054868

Registered Office: PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058 Website: www.pspprojects.com Extract of Unaudited Consolidated Financial Results for the Quarter and

(₹ in Lakhs) Consolidated Nine Months Ended Quarter Ended 31.12.2023 31.12.2022 31.12.2023 Particular (Unaudited) (Unaudited) (Unaudited) No. Total Income from Operations 71,118.31 50,659.07 1,85,617.46 4,824.99 Net Profit for the period (before Tax, Exceptional and Extraordinary 4,204.40 14,468.84 Items and Share of Profit/(Loss) from Joint Venture) Net Profit for the period (after tax, Exceptional and Extraordinary 3,106.66 3,532.82 10,737.75 Items before Share of Profit/(Loss) from Joint Venture) Net Profit for the period (after tax, Exceptional and Extraordinary 3,108.32 3,536.01 10,745.06 Items and Share of Profit/(Loss) from Joint Venture) 3,538.31 10,751.96 Total Comprehensive Income for the period [Comprising Profit for 3,110.62 the period (after tax) and Other Comprehensive Income (after tax)] Paid-up Equity Share Capital - Face Value ₹10/- each 3,600.00 3,600.00 3,600.00 Other Equity excluding Revaluation Reserves Earnings Per Share of ₹ 10/-each (in ₹) (Not Annualised) 8.63 9.82 29.85

Nine months ended December 31, 2023

Notes:

Diluted

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09, 2024.

(₹ in Lakhs) 2. Additional information on Unaudited Standalone Financial Results are as follows:

		Standalor	10		
	Quarter	r Ended	Nine Months Ended		
Particular		31.12.2022 (Unaudited)			
Revenue from Operations	69,661.92	49,739.28	1,81,332.80		
Profit/(Loss) before tax and Exceptional item	4,397.86	4,815.39	14,636.12		
Profit/(Loss) after tax and Exceptional item	3,251.85	3,529.50	10,864.77		

The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: www.pspprojects.com) For and on behalf of Board of Directors of PSP Projects Limited

Place: Ahmedabad Date: February 9, 2024

Prahaladbhai S. Patel Chairman, Managing Director & CEO DIN: 00037633



CIN:U65929MH1990PLC057829 Regd.Office: AVINISHA TOWER, MEHADIA CHOWK, DHANTOLI, NAGPUR - 440 012. Ph no.0712-6663999 Website: www.berarfinance.com E-mail: investor.relations@berarfinance.com

8.63

9.82

29.85

Extract of Financial Results for the quarter ended December 31, 2023 [Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)]

(₹ in Lakhs, except per equity share data and Debt Equity Ratio) Ouarter ended Ouarter ended Year ended PARTICULARS Dec. 31, 2023 Dec. 31, 2022 March 31,2023 UNAUDITED UNAUDITED AUDITED 6662.90 Total Income from Operations 6259.69 21788.93 Net Profit/(Loss) for the period (before Tax, Exceptional 741.10 1000.83 2172.78 and/or Extraordinary items #) Net Profit/(Loss) for the period before tax (after Exceptional 741.10 1000.83 2172.78 and/or Extraordinary items #) Net Profit /(Loss)for the period after tax (after Exceptional 517.58 892.62 1708.12 and/or Extraordinary items#) Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive 522.11 897.90 1709.27 Income (after tax)] Paid -up Equity Share Capital 1233.68 1233.68 1233.68 Reserves (excluding Revaluation Reserve) 11895.60 10345.60 11895.60 Securities Premium Account 14123.94 14123.94 14123.94 Net worth (Including Retained earnings and ESOP) 27579.63 29113.77 27523.60 10 Paid up Debt Capital/ Outstanding Debt 92679.81 85014.88 83190.22 11 Outstanding Redeemable Preference Shares NA NA NA 12 Debt Equity Ratio 3.18 3.08 3.02 13 Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)* a) Basic 4.20 7.24 13.85 7.24 b) Diluted 4.18 13.79 14 Capital Redemption Reserve NA NA NA 15 Debenture Redemption Reserve NA NA NA 16 Debt Service Coverage Ratio NA NA NA 17 Interest Service Coverage Ratio NA NA NA

Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind AS Rules.

Not annualised for quarter ended December 31, 2023 and December 31, 2022.

/CIR/2022/0000000103 dated July 29, 2022 as amended ("Circular").

Place: Nagpur

Date: February 09, 2024

Notes: a) The above Results have been reviewed by the Audit Committee and subsequently approved by the Board of

Directors at their respective meetings held on February 09, 2024.) The above is an extract of the detailed format of financial results filed with the BSE Limited ("Stock Exchange") under Regulation 52 of the SEBI Listing Regulations. The full format of the financial results is available on the website of the Stock Exchange i.e www.bseindia.com and on the website of the Company i.e www.berarfinance.com


For the other line items referred in regulation 52 (4) of the SEBI Listing Regulations, pertinent disclosures have been made to BSE Limited and can be accessed on www.bseindia.com. and on the website of the Company i.e

1) This Extract of Financial Results has been prepared in accordance with the requirement of Regulation 52 of the SEBI Listing Regulations read with Operational Circular bearing reference no. SEBI /HO /DDHS /DDHS Div1 /P

> For and on behalf of Board of Directors of Berar Finance Limited

(Sandeep Jawanjal) Managing Director DIN: 01490054

Ahmedabad



(Rs. In lakhs except per share data)

Quarter

Consolidated (Unaudited)

Nine Months | Quarter

(₹ in Lakhs)

Consolidated



Aster DM Healthcare Limited

CIN: L85110KA2008PLC147259

Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India. Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

			Conso	lidated		77	Standalone						
Particulars		Quarter ende	d	Nine Mor	Nine Months ended Year ended		Quarter ended			Nine Mor	Year ended		
	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
Total income	3,718.56	3,325.22	3,200.67	10,268.35	8,734.78	12,011.13	537.83	529.69	409.33	1,536.24	1,141.82	1,583.51	
Net profit/ (loss) before tax	233.46	(5.16)	173.44	301.55	329.30	535.08	E31 5	56.69	41.44	162.70	128.28	182.33	
Net profit/ (loss) after tax	209.22	(15.33)	159.03	213.74		475.49		59.06	34.58	165.07	121.42	173.29	
Total Comprehensive Income/ (loss)	208.96	12.75	191.59	238.90	466.88	674.44	53.19	00.00	34.58	165.07	121.42	3 7	
Equity Share Capital	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	
Other Equity	-	-	- 8	- 12	-	3,948.55	- 1	-	- 2	- 33	<u> </u>	2,631.04	
Earnings per share (Face value of INR 10 each)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised	
Basic	3.60	(0.62)	2.80	3.08	5.11	8.54	1.07	1.19	0.70	3.32	2.44	3.48	

◆The unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee on February 08, 2024 and approved by the Board of Directors at its meeting held on February 08, 2024.

The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial statements is made available on the Company's website at www.asterdmhealthcare.com/investors and stock exchange website at BSE https://www.bseindia.com/ and NSE https://www.nseindia.com/.

The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

3.60

Place: Dubai Date: February 08, 2024

Diluted

For **Aster DM Healthcare Limited** Sd/-Alisha Moopen **Deputy Managing Director** DIN: 02432525

(Amount in INR crores except per share data)



Note:

Date: February 9, 2024

Place: Ahmedabad

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar),

Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481 Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN: L24230GJ1995PLC025878 Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023

Rupees in Million Year to date Corresponding 3 Months figures for Year to date the current | figures for the ended Sr. No. **Particulars** 3 Months Preceding 3 31/12/2022 ir Previous year period previous the previous ended Months ended ended period ended ended 31/12/2023 30/09/2023 31/12/2023 31/12/2022 31/03/2023 (Unaudited) Unaudited) (Unaudited) Jnaudited) (Audited) Total income from operations 140,136 122,269 172,374 9,255 10,072 7,801 32,761 21,068 Net Profit for the period before exceptional items and tax 31,939 Net Profit for the period after exceptional items but before tax 9,255 10,072 7,801 32,619 21,039 25,897 26,574 Net Profit for the period from continuing operations 7,678 8,017 6,225 16,661 19,649 Profit/ [Loss] after tax from discontinued operations 218 (10)198 (24)6,229 26,772 16,637 Net Profit for the period after tax and Non-Controlling Interest 7,896 8,007 19,603 Total Comprehensive Income for the period after tax and Non-Controlling Interest 5,479 8,099 7,446 26,476 13,444 16,459 Paid-up equity share capital (Face value Re. 1/-) 1,012 1,012 1,012 1,012 1,012 1,012 Reserves excluding Revaluation Reserve (i.e. Other Equity) 174,146 Earnings per share for continuing operations (not annualised for the quarter and nine months) Basic (Rs.) 7.59 7.92 6.15 26.25 16.39 19.35 Diluted (Rs.) 7.59 7.92 6.15 26.25 16.39 19.35 Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months) 6.15 16.36 19.30 a Basic (Rs.) 7.80 7.91 26.45 Diluted (Rs.) 7.80 7.91 6.15 26.45 16.36 19.30

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

> By Order of the Board, For Zydus Lifesciences Limited,

> > Dr. Sharvil P. Patel

Managing Director

DIN: 00131995



National Commodity & Derivatives Exchange Limited

CIN: U51909MH2003PLC140116

Regd Office: Akruti Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West, Mumbai. Maharashtra 400078

Ph: 022-66406789 | Email: askus@ncdex.com | Website: www.ncdex.com

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023 (Rs. In lakhs)

		W	Standalone	e.		Consolidated	
SI. No.	Particulars	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023
Ш		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1.	Total Income from operations	1,210	1,167	4,133	3,313	3,430	10,209
2.	Net profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	(1,438)	(1,415)	(3,619)	(1,311)	(1,512)	(3,275)
3.	Net profit/ (Loss) for the period before Tax (after Exceptional and/or Extraordinary items#)	1,268	(1,415)	(323)	(1,311)	(1,548)	(3,231)
4.	Net profit/ (Loss) for the period after Tax (after Exceptional and/or Extraordinary items#)	1,488	(1,045)	321	(1,126)	(1,113)	(2,497)
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	1,521	(1,065)	357	(1,107)	(1,164)	(2,505)
6.	Equity Share Capital	5,068	5,068	5,068	5,068	5,068	5,068
7.	Reserves (excluding Revaluation Reserve) as shown in Audited Balance Sheet of the previous year		-	-	-	-	- -
8.	Earnings Per Share (FV ₹ 10 each) (for continuing and discontinued operations) 1. Basic (₹): Not annualised 2. Diluted (₹): Not annualised	2.94 2.94	(2.06) (2.06)	0.63 0.63	(2.15) (2.15)	(2.11) (2.11)	(4.69) (4.69)

Notes:

- 1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financials are available on our website www.ncdex.com
- 2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.
- 3 #(i) In standalone financial statements, during the quarter ended December 31,2023, the Exchange has received excess contribution of Rs.15 lakh and Rs. 590 lakh during the half year ended September 30,2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd.(NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31,2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment and the same is credited to the statement of profit and loss and shown as an Exceptional item.

(ii) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has sold 8.71% (31 lakh equity share) of its stake in its subsidiary, NCDEX e-Markets Limited (NeML), to its wholly owned subsidiary, NCCL, for a consideration of Rs. 3,000.80 lakh. The profit earned on the said stake sale of Rs. 2,691 lakh has been credited to the statement of profit and loss and shown as an exceptional item.

(iii) In case of subsidiary NCDEX e Markets Limited (NeML), NeML has incurred expenses of Rs. 36 Lakhs on newly incorporated Joint Venture during the nine months ended December 31, 2022. As the approval for commencement of business is awaited from the relevant authority, the said expenses have been shown as an exceptional item. (iv) In case of subsidiary NCDEX e Markets Limited (NeML), during the nine months ended December 31, 2023, exceptional Income of Rs 44 lakh is on account of income

booked for recovery of Preincorporation and other expenses incurred on behalf of newly incorporated JV, prior to receipt of approval from Regulatory authorities.

For and on behalf of the Board of Directors

Place: Mumbai Date: February 9, 2024

financialexp.epapr.in

Arun Raste Managing Director & Chief Executive Officer DIN - 08561128

CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat Phone No.: +91-79-68138700 || Fax: +91-79-68138725 || CIN: L24230GJ1984PLC007440 Email Id: complianceofficer@concordbiotech.com | Website: www. concordbiotech.com Regd. Office & Plant: 1482-86, Trasad Road, Dholka, District: Ahmedabad - 382225, Gujarat, India Phone No.: +91-2714-222604, 398200 || Fax: +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

Standalone (Unaudited)

Quarter

Particulars

Nine Months Quarter

NU		31/12/2023	anded on 31/12/2023	31/12/2022	31/12/2023	31/12/2023	31/12/2022
1	Total Income from Operations	24,079.65	69,796.98	24,068.29	24,079.65	69,796.98	24,068.29
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,455.30	20,751.75	7,907.55	7,757.27	21,308.69	7,736.83
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(64.87)	(40.36)	17.94	(64.87)	(40.36)	17.94
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.		1,28,151.88	3		1,28,151.88	
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations - Not Annualised)					8	
88	1) Basic	7.13	19.84	7.56	7.41	20.37	7.40
23	2) Diluted	7.13	19.84	7.56	7.41	20.37	7.40

Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com


Notes: (a) The above is an extract of the detailed format of Unaudited Quarterly / Nine Months Standalone and

(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules /AS Rules, whichever is applicable.

(c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 08, 2024.

For and on behalf of board of directors of Concord Biotech Limited **Ankur Vaid** Place: Ahmedabad

Date: Fennruary 8, 2024 Joint Managing Director & CEO - DIN: 01857225



PSP Projects Limited

CIN:L45201GJ2008PLC054868

Registered Office: PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058 Website: www.pspprojects.com

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023

			Consonad	tou
		Quarte	r Ended	Nine Months Ended
Sr. No.	Particular		31.12.2022 (Unaudited)	31.12.2023 (Unaudited)
1.	Total Income from Operations	71,118.31	50,659.07	1,85,617.46
2.	Net Profit for the period (before Tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	4,204.40	4,824.99	14,468.84
3.	Net Profit for the period (after tax, Exceptional and Extraordinary Items before Share of Profit/(Loss) from Joint Venture)	3,106.66	3,532.82	10,737.75
4.	Net Profit for the period (after tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	3,108.32	3,536.01	10,745.06
5.	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	3,110.62	3,538.31	10,751.96
6.	Paid-up Equity Share Capital - Face Value ₹10/- each	3,600.00	3,600.00	3,600.00
7.	Other Equity excluding Revaluation Reserves			
8.	Earnings Per Share of ₹ 10/-each (in ₹) (Not Annualised)			
	Basic	8.63	9.82	29.85
	Diluted	8.63	9.82	29.85

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09, 2024.

2. Additional information on Unaudited Standalone Financial Results are as follows: (₹ in Lakhs) Ctandalana

33	Standaloi	10
Quarte	r Ended	Nine Months Ended
69,661.92	49,739.28	1,81,332.80
4,397.86	4,815.39	14,636.12
3,251.85	3,529.50	10,864.77
	31.12.2023 (Unaudited) 69,661.92 4,397.86	Quarter Ended 31.12.2023 31.12.2022 (Unaudited) 69,661.92 49,739.28 4,397.86 4,815.39

of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: www.pspprojects.com) For and on behalf of Board of Directors of PSP Projects Limited

Prahaladbhai S. Patel Chairman, Managing Director & CEO Date: February 9, 2024 DIN: 00037633



17 Interest Service Coverage Ratio

Place: Ahmedabad

CIN:U65929MH1990PLC057829 Regd.Office: AVINISHA TOWER, MEHADIA CHOWK, DHANTOLI, NAGPUR - 440 012. Ph no.0712-6663999 Website: www.berarfinance.com E-mail: investor.relations@berarfinance.com

Extract of Financial Results for the quarter ended December 31, 2023 [Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)]

(₹ in Lakhs, except per equity share data and Debt Equity Ratio) Quarter ended Quarter ended Year ended PARTICULARS Dec. 31, 2023 Dec. 31, 2022 March 31,2023 UNAUDITED UNAUDITED AUDITED Total Income from Operations 6662.90 6259.69 21788.93 Net Profit/(Loss) for the period (before Tax, Exceptional 741.10 1000.83 2172.78 and/or Extraordinary items #) Net Profit/(Loss) for the period before tax (after Exceptional 741.10 1000.83 2172.78 and/or Extraordinary items #) Net Profit /(Loss)for the period after tax (after Exceptional 517.58 and/or Extraordinary items#) Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive 522.11 897.90 1709.27 Income (after tax)] 1233.68 Paid -up Equity Share Capital 1233.68 1233.68 Reserves (excluding Revaluation Reserve) 11895.60 10345.60 11895.60 Securities Premium Account 14123.94 14123.94 14123.94 Net worth (Including Retained earnings and ESOP) 29113.77 27579.63 27523.60 10 Paid up Debt Capital/ Outstanding Debt 92679.81 85014.88 83190.22 11 Outstanding Redeemable Preference Shares NA NA. NA 12 Debt Equity Ratio 3.18 3.08 3.02 13 Earnings Per Share (of Rs. 10/- each) (for continuing and discontinued operations)* 4.20 7.2413.85 7.24 b) Diluted 4.18 13.79 14 Capital Redemption Reserve NA NA NA 15 Debenture Redemption Reserve NA NA NA 16 Debt Service Coverage Ratio NA NA.

Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind AS Rules.

Not annualised for quarter ended December 31, 2023 and December 31, 2022.

a) The above Results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on February 09, 2024. b) The above is an extract of the detailed format of financial results filed with the BSE Limited ("Stock Exchange")

under Regulation 52 of the SEBI Listing Regulations. The full format of the financial results is available on the website of the Stock Exchange i.e www.bseindia.com and on the website of the Company i.e

c) For the other line items referred in regulation 52 (4) of the SEBI Listing Regulations, pertinent disclosures have been made to BSE Limited and can be accessed on www.bseindia.com. and on the website of the Company i.e www.berarfinance.com

This Extract of Financial Results has been prepared in accordance with the requirement of Regulation 52 of the SEBI Listing Regulations read with Operational Circular bearing reference no. SEBI /HO /DDHS /DDHS Div1 /P /CIR/2022/0000000103 dated July 29, 2022 as amended ("Circular").

> Berar Finance Limited (Sandeep Jawanjal)

For and on behalf of Board of Directors of

Managing Director

DIN: 01490054

NA

Place: Nagpur Date: February 09, 2024

HYDERABAD

(Rs. In lakhs except per share data)

31/12/2022 31/12/2023 31/12/2023 31/12/2022

Quarter

ended on ended on

Consolidated (Unaudited)

Nine Months Quarter

ended on ended on



Aster DM Healthcare Limited

CIN: L85110KA2008PLC147259

Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India. Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(Amount in INR crores except per share data)

						77)	Standalone					
Particulars		Quarter ende	d	Nine Months ended Y		Year ended	Quarter ended			Nine Mor	Year ended	
1	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total income	3,718.56	3,325.22	3,200.67	10,268.35	8,734.78	12,011.13	537.83	529.69	409.33	1,536.24	1,141.82	1,583.51
Net profit/ (loss) before tax	233.46	(5.16)	173.44	301.55	329.30	535.08	53.19	56.69	41.44	162.70	128.28	182.33
Net profit/ (loss) after tax	209.22	(15.33)	159.03	213.74	292.90	475.49	53.19	59.06	34.58	165.07	121.42	173.29
Total Comprehensive Income/ (loss)	208.96	12.75	191.59	238.90	466.88	674.44	53.19	59.06	34.58	165.07	121.42	173.70
Equity Share Capital	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52
Other Equity	-		- 8	- 8	-	3,948.55	78 - 8		- 3	- 7	-	2,631.04
Earnings per share (Face value of INR 10 each)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised
Basic	3.60	(0.62)	2.80	3.08	5.11	8.54	1.07	1.19	0.70	3.32	2.44	3.48
Diluted	3.60	(0.62)	2.80	3.08	5.10	8.53	1.07	1.19	0.69	3.31	2.44	3.48

The unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee on February 08, 2024 and approved by the Board of Directors at its meeting held on February 08, 2024.

◆The above is an extract of the detailed format of guarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial statements is made available on the Company's website at www.asterdmhealthcare.com/investors and stock exchange website at BSE https://www.bseindia.com/ and NSE https://www.nseindia.com/.

The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

For **Aster DM Healthcare Limited** Sd/-Alisha Moopen **Deputy Managing Director**

DIN: 02432525

Dedicated To Life

Date: February 9, 2024

Place: Ahmedabad

Date: February 08, 2024

Place: Dubai

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481

Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN: L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023

		Rupees III Million									
				Corresponding	Year to date						
				3 Months	figures for	Year to date					
Sr. No	Particulars			ended	the current	figures for the					
		3 Months	- 1	31/12/2022 in		previous	Previous year				
		ended	Months ended		ended	period ended	ended				
		31/12/2023	4.0	year	31/12/2023	33	31/03/2023				
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	100	(Audited)				
1	Total income from operations	45,052	43,688	42,571	140,136	122,269	172,374				
2	Net Profit for the period before exceptional items and tax	9,255	10,072	7,801	32,761	21,068	31,939				
3	Net Profit for the period after exceptional items but before tax	9,255	10,072	7,801	32,619	21,039	25,897				
4	Net Profit for the period from continuing operations	7,678	8,017	6,225	26,574	16,661	19,649				
5	Profit/ [Loss] after tax from discontinued operations	218	(10)	4	198	(24)	(46)				
6	Net Profit for the period after tax and Non-Controlling Interest	7,896	8,007	6,229	26,772	16,637	19,603				
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	8,099	7,446	5,479	26,476	13,444	16,459				
8	Paid-up equity share capital (Face value Re. 1/-)	1,012	1,012	1,012	1,012	1,012	1,012				
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)						174,146				
10	Earnings per share for continuing operations (not annualised for the quarter and nine months)						- 1				
a	Basic (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35				
l t	Diluted (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35				
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)						- 1				
a	Basic (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30				
t	Diluted (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30				
Note	-										

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

> By Order of the Board, For Zydus Lifesciences Limited,

> > Dr. Sharvil P. Patel

Managing Director

DIN: 00131995



National Commodity & Derivatives Exchange Limited

CIN: U51909MH2003PLC140116

Regd Office: Akruti Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West, Mumbai. Maharashtra 400078

Ph: 022-66406789 | Email: askus@ncdex.com | Website: www.ncdex.com

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023 (Rs. In lakhs)

			Standalone	e.		Consolidated	
SI. No.	Particulars	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1.	Total Income from operations	1,210	1,167	4,133	3,313	3,430	10,209
2.	Net profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	(1,438)	(1,415)	(3,619)	(1,311)	(1,512)	(3,275)
3.	Net profit/ (Loss) for the period before Tax (after Exceptional and/or Extraordinary items#)	1,268	(1,415)	(323)	(1,311)	(1,548)	(3,231)
4.	Net profit/ (Loss) for the period after Tax (after Exceptional and/or Extraordinary items#)	1,488	(1,045)	321	(1,126)	(1,113)	(2,497)
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	1,521	(1,065)	357	(1,107)	(1,164)	(2,505)
6.	Equity Share Capital	5,068	5,068	5,068	5,068	5,068	5,068
7.	Reserves (excluding Revaluation Reserve) as shown in Audited Balance Sheet of the previous year		-	-	-	-	-
8.	Earnings Per Share (FV ₹ 10 each) (for continuing and discontinued operations) 1. Basic (₹): Not annualised 2. Diluted (₹): Not annualised	2.94 2.94	(2.06) (2.06)	0.63 0.63	(2.15) (2.15)	(2.11) (2.11)	(4.69) (4.69)

Notes:

- 1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financials are available on our website www.ncdex.com
- 2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.
- 3 #(i) In standalone financial statements, during the guarter ended December 31,2023, the Exchange has received excess contribution of Rs.15 lakh and Rs. 590 lakh during the half year ended September 30,2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd.(NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31,2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment and the same is credited to the statement of profit and loss and shown as an Exceptional item.

(ii) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has sold 8.71% (31 lakh equity share) of its stake in its subsidiary, NCDEX e-Markets Limited (NeML), to its wholly owned subsidiary, NCCL, for a consideration of Rs. 3,000.80 lakh. The profit earned on the said stake sale of Rs. 2,691 lakh has been credited to the statement of profit and loss and shown as an exceptional item.

(iii) In case of subsidiary NCDEX e Markets Limited (NeML), NeML has incurred expenses of Rs. 36 Lakhs on newly incorporated Joint Venture during the nine months ended December 31, 2022. As the approval for commencement of business is awaited from the relevant authority, the said expenses have been shown as an exceptional item. (iv) In case of subsidiary NCDEX e Markets Limited (NeML), during the nine months ended December 31, 2023, exceptional Income of Rs 44 lakh is on account of income

booked for recovery of Preincorporation and other expenses incurred on behalf of newly incorporated JV, prior to receipt of approval from Regulatory authorities.

For and on behalf of the Board of Directors

Place: Mumbai Date: February 9, 2024

Arun Raste Managing Director & Chief Executive Officer DIN - 08561128 **CONCORD BIOTECH LIMITED**

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat Phone No.: +91-79-68138700 || Fax: +91-79-68138725 || CIN: L24230GJ1984PLC007440 Email Id : complianceofficer@concordbiotech.com || Website : www. concordbiotech.com Regd. Office & Plant: 1482-86, Trasad Road, Dholka, District: Ahmedabad - 382225, Gujarat, India Phone No.: +91-2714-222604, 398200 || Fax: +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

Standalone (Unaudited)

31/12/2023 31/12/2023

ended on

Quarter

ended on

Nine Months Quarter

1	Total Income from Operations	24,079.65	69,796.98	24,068.29	24,079.65	69,796.98	24,068.29
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,455.30	20,751.75	7,907.55	7,757.27	21,308.69	7,736.83
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(64.87)	(40.36)	17.94	(64.87)	(40.36)	17.94
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.		1,28,151.88			1,28,151.88	
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations - Not Annualised)					8	
8	1) Basic	7.13	19.84	7.56	7.41	20.37	7.40
É	2) Diluted	7.13	19.84	7.56	7.41	20.37	7.40

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly / Nine Months Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com

(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules /AS Rules, whichever is applicable.

(c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 08, 2024.

For and on behalf of board of directors of Concord Biotech Limited **Ankur Vaid** Place: Ahmedabad

Date: Fennruary 8, 2024 Joint Managing Director & CEO - DIN: 01857225

PSP

Particulars

PSP Projects Limited

CIN:L45201GJ2008PLC054868

Registered Office: PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058 Website: www.pspprojects.com

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023 (₹ in Lakhs)

Consolidated Quarter Ended Nine Months Ended 31.12.2023 31.12.2022 31.12.2023 Particular No. (Unaudited) (Unaudited) (Unaudited) Total Income from Operations 71,118.31 50,659.07 1,85,617.46 Net Profit for the period (before Tax, Exceptional and Extraordinary 4,204.40 4,824.99 14,468.84 Items and Share of Profit/(Loss) from Joint Venture) Net Profit for the period (after tax, Exceptional and Extraordinary 3,106.66 3,532.82 10,737.75 Items before Share of Profit/(Loss) from Joint Venture) Net Profit for the period (after tax, Exceptional and Extraordinary 3,108.32 3,536.01 10,745.06 Items and Share of Profit/(Loss) from Joint Venture) Total Comprehensive Income for the period [Comprising Profit for 3,110.62 3,538.31 10,751.96 the period (after tax) and Other Comprehensive Income (after tax)) Paid-up Equity Share Capital - Face Value ₹10/- each 3,600.00 3,600.00 3,600.00 Other Equity excluding Revaluation Reserves Earnings Per Share of ₹ 10/-each (in ₹) (Not Annualised) 8.63 9.82 29.85 Diluted 8.63 9.82 29.85

Notes:

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09, 2024. 2. Additional information on Unaudited Standalone Financial Results are as follows: (₹ in Lakhs)

Standalone Quarter Ended Nine Months Ended 31.12.2023 31.12.2022 31.12.2023 Particular (Unaudited) (Unaudited) (Unaudited) Revenue from Operations 69,661.92 49,739.28 1,81,332.80

Profit/(Loss) before tax and Exceptional item 4,397.86 4,815.39 14,636.12 Profit/(Loss) after tax and Exceptional item 3,251.85 3,529.50 10,864.77 3. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL: www.bseindia.com). National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: www.pspprojects.com) For and on behalf of Board of Directors

of PSP Projects Limited Prahaladbhai S. Patel Place: Ahmedabad Chairman, Managing Director & CEO Date: February 9, 2024 DIN: 00037633



Regd.Office: AVINISHA TOWER.MEHADIA CHOWK. DHANTOLI, NAGPUR - 440 012, Ph no.0712-6663999 Website: www.berarfinance.com E-mail: investor.relations@berarfinance.com

CIN:U65929MH1990PLC057829

Extract of Financial Results for the quarter ended December 31, 2023 [Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)]

(₹ in Lakhs, except per equity share data and Debt Equity Ratio)

Sr.	PARTICULARS	Quarter ended Dec. 31, 2023		Year ended March 31,2023
NO.		UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations	6662.90	6259.69	21788.93
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
4	Net Profit /(Loss)for the period after tax (after Exceptional and/or Extraordinary items#)	517.58	892.62	1708.12
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	522.11	897.90	1709.27
6	Paid -up Equity Share Capital	1233.68	1233.68	1233.68
7	Reserves (excluding Revaluation Reserve)	11895.60	10345.60	11895.60
8	Securities Premium Account	14123.94	14123.94	14123.94
9	Net worth (Including Retained earnings and ESOP)	29113.77	27579.63	27523.60
10	Paid up Debt Capital/ Outstanding Debt	92679.81	85014.88	83190.22
11	Outstanding Redeemable Preference Shares	NA	NA.	NA
12	Debt Equity Ratio	3.18	3.08	3.02
13	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)*	200,000	900330	25320
	a) Basic	4.20	7.24	13.85
	b) Diluted	4.18	7.24	13.79
	Capital Redemption Reserve	NA	NA	NA
	Debenture Redemption Reserve	NA	NA	NA
	Debt Service Coverage Ratio	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA

Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind AS Rules.

Not annualised for quarter ended December 31, 2023 and December 31, 2022.

/CIR/2022/0000000103 dated July 29, 2022 as amended ("Circular").

a) The above Results have been reviewed by the Audit Committee and subsequently approved by the Board of

Directors at their respective meetings held on February 09, 2024. b) The above is an extract of the detailed format of financial results filed with the BSE Limited ("Stock Exchange")

under Regulation 52 of the SEBI Listing Regulations. The full format of the financial results is available on the website of the Stock Exchange i.e www.bseindia.com and on the website of the Company i.e c) For the other line items referred in regulation 52 (4) of the SEBI Listing Regulations, pertinent disclosures have

been made to BSE Limited and can be accessed on www.bseindia.com. and on the website of the Company i.e www.berarfinance.com d) This Extract of Financial Results has been prepared in accordance with the requirement of Regulation 52 of the

SEBI Listing Regulations read with Operational Circular bearing reference no. SEBI /HO /DDHS /DDHS Div1 /P

For and on behalf of Board of Directors of Berar Finance Limited

(Sandeep Jawanjal) Place: Nagpur Managing Director Date: February 09, 2024 DIN: 01490054

financialexp.epapr.in CHENNAI/KOCHI

WWW.FINANCIALEXPRESS.COM



Aster DM Healthcare Limited

Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

CIN: L85110KA2008PLC147259 Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India.

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE OUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(Amount in INR crores except per share data)

	f	Consolidated					Standalone					
Particulars		Quarter ende	d	Nine Mor	Nine Months ended Year e		Quarter ended			Nine Mor	Year ended	
	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total income	3,718.56	3,325.22	3,200.67	10,268.35	8,734.78	12,011.13	537.83	529.69	409.33	1,536.24	1,141.82	1,583.51
Net profit/ (loss) before tax	233.46	(5.16)	173.44	301.55	329.30	535.08	53.19	56.69	41.44	162.70	128.28	182.33
Net profit/ (loss) after tax	209.22	(15.33)	159.03	213.74				59.06	34.58	165.07	121.42	173.29
Total Comprehensive Income/ (loss)	208.96	12.75	191.59	238.90	466.88	674.44	53.19	59.06	34.58	165.07	121.42	173.70
Equity Share Capital	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52
Other Equity	-	-	- 1	-	-	3,948.55	-	-	- 1	- 1	-	2,631.04
Earnings per share (Face value of INR 10 each)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised
Basic	3.60	(0.62)	2.80	3.08	5.11	8.54	1.07	1.19	0.70	3.32	2.44	3.48
Diluted	3.60	(0.62)	2.80	3.08	5.10	8.53	1.07	1.19	0.69	3.31	2.44	3.48
◆The unaudited consolidated and standa	lone financial	results of the	Company fo	r the quarter	and nine mor	ths ended D	ecember 31	2023 have he	en reviewed	hy the Audit (Committee or	February 08

- The unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee on February 08, 2024 and approved by the Board of Directors at its meeting held on February 08, 2024.
- The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the guarterly financial statements is made available on the Company's website at www.asterdmhealthcare.com/investors and stock exchange website at BSE https://www.bseindia.com/ and NSE https://www.nseindia.com/.
- ◆The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

For Aster DM Healthcare Limited

Alisha Moopen **Deputy Managing Director**

DIN: 02432525

Rupees in Million

Place: Dubai Date: February 08, 2024

> **Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]** Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481

Dedicated To Life

CIN: L24230GJ1995PLC025878 Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023

Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

ı		N N			Corresponding			
ı					3 Months	figures for	Year to date	
Sı	r. No.	Particulars			ended		figures for the	
ı			3 Months	_	31/12/2022 in		previous	Previous year
ı			ended	Months ended	i i	ended	period ended	ended
ı			31/12/2023		year	31/12/2023		31/03/2023
			(Unaudited)	177	(Unaudited)	(Unaudited)	` '	(Audited)
Г		Total income from operations	45,052	43,688	42,571	140,136	122,269	172,374
2		Net Profit for the period before exceptional items and tax	9,255	10,072	7,801	32,761	21,068	31,939
3		Net Profit for the period after exceptional items but before tax	9,255	10,072	7,801	32,619	21,039	25,897
4		Net Profit for the period from continuing operations	7,678	8,017	6,225	26,574	16,661	19,649
5	;	Profit/ [Loss] after tax from discontinued operations	218	(10)	4	198	(24)	(46)
6	,	Net Profit for the period after tax and Non-Controlling Interest	7,896	8,007	6,229	26,772	16,637	19,603
7	'	Total Comprehensive Income for the period after tax and Non-Controlling Interest	8,099	7,446	5,479	26,476	13,444	16,459
8	:	Paid-up equity share capital (Face value Re. 1/-)	1,012	1,012	1,012	1,012	1,012	1,012
9)	Reserves excluding Revaluation Reserve (i.e. Other Equity)						174,146
10)	Earnings per share for continuing operations (not annualised for the quarter and nine months)						
ı	а	Basic (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
ı	b	Diluted (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
1:	1	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)						
ı	a	Basic (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
ı	b	Diluted (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
N	lote:		100	254	00 0	ž – 2		

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure

Requirements Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel Managing Director DIN: 00131995

Date: February 9, 2024 Place: Ahmedabad



National Commodity & Derivatives Exchange Limited CIN: U51909MH2003PLC140116

Regd Office: Akruti Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West, Mumbai, Maharashtra 400078

Ph: 022-66406789 | Email: askus@ncdex.com | Website: www.ncdex.com

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023

		v e	Standalone		Consolidated				
	SI. No.	Particulars	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023	
			(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	
	1.	Total Income from operations	1,210	1,167	4,133	3,313	3,430	10,209	
	2.	Net profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	(1,438)	(1,415)	(3,619)	(1,311)	(1,512)	(3,275)	
	3.	Net profit/ (Loss) for the period before Tax (after Exceptional and/or Extraordinary items#)	1,268	(1,415)	(323)	(1,311)	(1,548)	(3,231)	
	4.	Net profit/ (Loss) for the period after Tax (after Exceptional and/or Extraordinary items#)	1,488	(1,045)	321	(1,126)	(1,113)	(2,497)	
	5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	1,521	(1,065)	357	(1,107)	(1,164)	(2,505)	
I	6.	Equity Share Capital	5,068	5,068	5,068	5,068	5,068	5,068	
	7.	Reserves (excluding Revaluation Reserve) as shown in Audited Balance Sheet of the previous year	-	-	-	-	-	-	
	8.	Earnings Per Share (FV ₹ 10 each) (for continuing and discontinued operations) 1. Basic (₹): Not annualised 2. Diluted (₹): Not annualised	2.94 2.94	(2.06) (2.06)	0.63 0.63	(2.15) (2.15)	(2.11) (2.11)	(4.69) (4.69)	

Notes:

Place: Mumbai

financialexp.epap.in

Date: February 9, 2024

- 1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financials are available on our website www.ncdex.com
- 2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.
- 3 #(i) In standalone financial statements, during the guarter ended December 31,2023, the Exchange has received excess contribution of Rs.15 lakh and Rs. 590 lakh during the half year ended September 30,2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd.(NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31,2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment and the same is credited to the statement of profit and loss and shown as an Exceptional item.

(ii) In standalone financial statements, during the guarter ended December 31, 2023, the Exchange has sold 8.71% (31 lakh equity share) of its stake in its subsidiary, NCDEX e-Markets Limited (NeML), to its wholly owned subsidiary, NCCL, for a consideration of Rs. 3,000.80 lakh. The profit earned on the said stake sale of Rs. 2,691 lakh has been credited to the statement of profit and loss and shown as an exceptional item.

(iii) In case of subsidiary NCDEX e Markets Limited (NeML), NeML has incurred expenses of Rs. 36 Lakhs on newly incorporated Joint Venture during the nine months ended December 31, 2022. As the approval for commencement of business is awaited from the relevant authority, the said expenses have been shown as an exceptional item.

(iv) In case of subsidiary NCDEX e Markets Limited (NeML), during the nine months ended December 31, 2023, exceptional Income of Rs 44 lakh is on account of income booked for recovery of Preincorporation and other expenses incurred on behalf of newly incorporated JV, prior to receipt of approval from Regulatory authorities.

For and on behalf of the Board of Directors

Arun Raste

Managing Director & Chief Executive Officer DIN - 08561128 CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat Phone No.: +91-79-68138700 || Fax: +91-79-68138725 || CIN: L24230GJ1984PLC007440 Email Id: complianceofficer@concordbiotech.com | Website: www. concordbiotech.com Regd. Office & Plant: 1482-86, Trasad Road, Dholka, District: Ahmedabad - 382225, Gujarat, India Phone No.: +91-2714-222604, 398200 || Fax: +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

1				(Rs. In Ia	akhs excep	ot per sha	re data)	
		Standalo	one (Unaud	ited)	Consolidated (Unaudited)			
SI. No	Particulars	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022	
1.	Total Income from Operations	24,079.65	69,796.98	24,068.29	24,079.65	69,796.98	24,068.29	
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27	
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27	
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,455.30	20,751.75	7,907.55	7,757.27	21,308.69	7,736.83	
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(64.87)	(40.36)	17.94	(64.87)	(40.36)	17.94	
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.	301	1,28,151.88		240	1,28,151.88		
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations - Not Annualised)		700 AV			9	0	
33	1) Basic	7.13	19.84	7.56	7.41	20.37	7.40	
400	2) Diluted	7.13	19.84	7.56	7.41	20.37	7.40	

Notes: (a) The above is an extract of the detailed format of Unaudited Quarterly / Nine Months Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com

(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules /AS Rules, whichever is applicable. (c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee

and approved by the Board of Directors of the Company at their meeting held on February 08, 2024. For and on behalf of board of directors of Concord Biotech Limited

Place: Ahmedabad Ankur Vaid Date: Fennruary 8, 2024 Joint Managing Director & CEO - DIN: 01857225

> **PSP Projects Limited** CIN:L45201GJ2008PLC054868

Registered Office: PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058 Website: www.pspprojects.com Extract of Unaudited Consolidated Financial Results for the Quarter and

Nine months ended December 31, 2023 (₹ in Lakhs) Consolidated

Sr. No.		Quarte	r Ended	Nine Months Ended		
575000 L	Particular	31.12.2023 (Unaudited)	31.12.2022 (Unaudited)	31.12.2023 (Unaudited)		
1.	Total Income from Operations	71,118.31	50,659.07	1,85,617.46		
2.	Net Profit for the period (before Tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	4,204.40	4,824.99	14,468.84		
3.	Net Profit for the period (after tax, Exceptional and Extraordinary Items before Share of Profit/(Loss) from Joint Venture)	3,106.66	3,532.82	10,737.75		
4.	Net Profit for the period (after tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	3,108.32	3,536.01	10,745.06		
5.	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	3,110.62	3,538.31	10,751.96		
6.	Paid-up Equity Share Capital - Face Value ₹10/- each	3,600.00	3,600.00	3,600.00		
7.	Other Equity excluding Revaluation Reserves	300	6970			
8.	Earnings Per Share of ₹ 10/-each (in ₹) (Not Annualised)					
Charles	Basic	8.63	9.82	29.85		
	Diluted	8.63	9.82	29.85		

Notes:

PSP

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09, 2024. (₹ in Lakhs)

Additional information on Unaudited Standalone Financial Results are as follows: Standalone Quarter Ended Nine Months Ended 31.12.2023 31.12.2022 31.12.2023 Particular (Unaudited) (Unaudited) (Unaudited) 49,739.28 Revenue from Operations 69,661.92 1,81,332.80

Profit/(Loss) before tax and Exceptional item 4,397.86 4,815.39 14,636.12 Profit/(Loss) after tax and Exceptional item 3,251.85 3,529.50 10,864.77 3. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: www.pspprojects.com) For and on behalf of Board of Directors

of PSP Projects Limited Prahaladbhai S. Patel Place: Ahmedabad Chairman, Managing Director & CEO Date: February 9, 2024 DIN: 00037633



Regd.Office: AVINISHA TOWER, MEHADIA CHOWK, DHANTOLI, NAGPUR - 440 012. Ph no.0712-6663999 Website: www.berarfinance.com E-mail: investor.relations@berarfinance.com

CIN:U65929MH1990PLC057829

[Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)] (₹ in Lakhs, except per equity share data and Debt Equity Ratio)

Sr.	PARTICULARS	Quarter ended Dec. 31, 2023		Year ended March 31,2023
NO.		UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations	6662.90	6259.69	21788.93
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
4	Net Profit /(Loss)for the period after tax (after Exceptional and/or Extraordinary items#)	517.58	892.62	1708.12
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	522.11	897.90	1709.27
6	Paid -up Equity Share Capital	1233.68	1233.68	1233.68
7	Reserves (excluding Revaluation Reserve)	11895.60	10345.60	11895.60
8	Securities Premium Account	14123.94	14123.94	14123.94
9	Net worth (Including Retained earnings and ESOP)	29113.77	27579.63	27523.60
10	Paid up Debt Capital/ Outstanding Debt	92679.81	85014.88	83190.22
11	Outstanding Redeemable Preference Shares	NA	NA	NA
12	Debt Equity Ratio	3.18	3.08	3.02
13	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)*			
	a) Basic	4.20	7.24	13.85
	b) Diluted	4.18	7.24	13.79
14	Capital Redemption Reserve	NA	NA	NA
15	Debenture Redemption Reserve	NA	NA	NA
16	Debt Service Coverage Ratio	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA.	NA

Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance

* Not annualised for quarter ended December 31, 2023 and December 31, 2022.

a) The above Results have been reviewed by the Audit Committee and subsequently approved by the Board of

Directors at their respective meetings held on February 09, 2024. b) The above is an extract of the detailed format of financial results filed with the BSE Limited ("Stock Exchange") under Regulation 52 of the SEBI Listing Regulations. The full format of the financial results is available on the website of the Stock Exchange i.e www.bseindia.com and on the website of the Company i.e

www.berarfinance.com c) For the other line items referred in regulation 52 (4) of the SEBI Listing Regulations, pertinent disclosures have been made to BSE Limited and can be accessed on www.bseindia.com. and on the website of the Company i.e

d) This Extract of Financial Results has been prepared in accordance with the requirement of Regulation 52 of the SEBI Listing Regulations read with Operational Circular bearing reference no. SEBI /HO /DDHS /DDHS Div1 /P /CIR/2022/0000000103 dated July 29, 2022 as amended ("Circular").

> For and on behalf of Board of Directors of Berar Finance Limited

(Sandeep Jawanjal) Managing Director DIN: 01490054

Kolkata

Place: Nagpur Date: February 09, 2024

(Rs. In lakhs except per share data)

20.37

20.37

7.41



Aster DM Healthcare Limited

CIN: L85110KA2008PLC147259

Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India. Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE OUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

(Amount in INR crores except per share data)

			Conso	lidated			Standalone					
Particulars		Quarter ende	d	Nine Mor	Nine Months ended Year ende		Quarter ended			Nine Mor	Year ended	
	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total income	3,718.56	3,325.22	3,200.67	10,268.35	8,734.78	12,011.13	537.83	529.69	409.33	1,536.24	1,141.82	1,583.51
Net profit/ (loss) before tax	233.46	(5.16)	173.44	301.55	329.30	535.08	53.19	56.69	41.44	162.70	128.28	182.33
Net profit/ (loss) after tax	209.22	(15.33)	159.03	213.74		475.49	53.19	59.06	34.58	165.07	121.42	173.29
Total Comprehensive Income/ (loss)	208.96	12.75	191.59	238.90	466.88	674.44	53.19	59.06	34.58	165.07	121.42	173.70
Equity Share Capital	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52
Other Equity	-	- 1	- 1	- 1	-	3,948.55	- 1		- 1	- 1	-	2,631.04
Earnings per share (Face value of INR 10 each)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised
Basic	3.60	(0.62)	2.80	3.08	5.11	8.54	1.07	1.19	0.70	3.32	2.44	3.48
Diluted	3.60	(0.62)	2.80	3.08	5.10	8.53	1.07	1.19	0.69	3.31	2.44	3.48

- The unaudited consolidated and standalone financial results of the Company for the quarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee on February 08, 2024 and approved by the Board of Directors at its meeting held on February 08, 2024.
- The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial statements is made available on the Company's website at www.asterdmhealthcare.com/investors and stock exchange website at BSE https://www.bseindia.com/ and NSE https://www.nseindia.com/.
- ◆The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

For **Aster DM Healthcare Limited**

Alisha Moopen **Deputy Managing Director** DIN: 02432525

Place: Dubai Date: February 08, 2024

Dedicated To Life

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481 Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

CIN: L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023 Rupees in Million

ı		× ×		7	Corresponding	Year to date	70	
ı					3 Months	figures for	Year to date	
ls	Sr. No.	Particulars			ended		figures for the	
ľ		1	3 Months		31/12/2022 in		previous	Previous year
ı			ended	Months ended		ended	period ended	
ı			31/12/2023		year	31/12/2023		31/03/2023
L			(Unaudited)	(2) ·	(Unaudited)	(Unaudited)	100	(Audited)
Г	1	Total income from operations	45,052	43,688	42,571	140,136	122,269	172,374
ı	2	Net Profit for the period before exceptional items and tax	9,255	10,072	7,801	32,761	21,068	31,939
ı	3	Net Profit for the period after exceptional items but before tax	9,255	10,072	7,801	32,619	21,039	25,897
ı	4	Net Profit for the period from continuing operations	7,678	8,017	6,225	26,574	16,661	19,649
ı	5	Profit/ [Loss] after tax from discontinued operations	218	(10)	4	198	(24)	(46)
ı	6	Net Profit for the period after tax and Non-Controlling Interest	7,896	8,007	6,229	26,772	16,637	19,603
ı	7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	8,099	7,446	5,479	26,476	13,444	16,459
ı	8	Paid-up equity share capital (Face value Re. 1/-)	1,012	1,012	1,012	1,012	1,012	1,012
ı	9	Reserves excluding Revaluation Reserve (i.e. Other Equity)						174,146
ŀ	10	Earnings per share for continuing operations (not annualised for the quarter and nine months)						
ı	a	Basic (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
ı	b	Diluted (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
1	1	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)						
	a	Basic (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
ı	b	Diluted (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
r	Note:	3)	- 2	20		× 3	5 78	

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

> By Order of the Board, For Zydus Lifesciences Limited,

> > Dr. Sharvil P. Patel Managing Director DIN: 00131995

Date: February 9, 2024 Place: Ahmedabad



National Commodity & Derivatives Exchange Limited

CIN: U51909MH2003PLC140116

Regd Office: Akruti Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West, Mumbai, Maharashtra 400078

Ph: 022-66406789 | Email: askus@ncdex.com | Website: www.ncdex.com

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023

(Rs. In lakhs)

		# 0/ = =	Standalone	3		Consolidated	
SI. No.	Particulars	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023
	0.00	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1.	Total Income from operations	1,210	1,167	4,133	3,313	3,430	10,209
2.	Net profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	(1,438)	(1,415)	(3,619)	(1,311)	(1,512)	(3,275)
3.	Net profit/ (Loss) for the period before Tax (after Exceptional and/or Extraordinary items#)	1,268	(1,415)	(323)	(1,311)	(1,548)	(3,231)
4.	Net profit/ (Loss) for the period after Tax (after Exceptional and/or Extraordinary items#)	1,488	(1,045)	321	(1,126)	(1,113)	(2,497)
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	1,521	(1,065)	357	(1,107)	(1,164)	(2,505)
6.	Equity Share Capital	5,068	5,068	5,068	5,068	5,068	5,068
7.	Reserves (excluding Revaluation Reserve) as shown in Audited Balance Sheet of the previous year	-	-	-	-	-	-
8.	Earnings Per Share (FV ₹ 10 each) (for continuing and discontinued operations) 1. Basic (₹): Not annualised 2. Diluted (₹): Not annualised	2.94 2.94	(2.06) (2.06)	0.63 0.63	(2.15) (2.15)	(2.11) (2.11)	(4.69) (4.69)

Notes:

- 1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financials are available on our website www.ncdex.com
- 2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.
- 3 #(i) In standalone financial statements, during the guarter ended December 31,2023, the Exchange has received excess contribution of Rs.15 lakh and Rs. 590 lakh during the half year ended September 30,2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd.(NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31,2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment and the same is credited to the statement of profit and loss and shown as an Exceptional item.

(ii) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has sold 8.71% (31 lakh equity share) of its stake in its subsidiary, NCDEX e-Markets Limited (NeML), to its wholly owned subsidiary, NCCL, for a consideration of Rs. 3,000.80 lakh. The profit earned on the said stake sale of Rs. 2,691 lakh has been credited to the statement of profit and loss and shown as an exceptional item.

(iii) In case of subsidiary NCDEX e Markets Limited (NeML), NeML has incurred expenses of Rs. 36 Lakhs on newly incorporated Joint Venture during the nine months ended December 31, 2022. As the approval for commencement of business is awaited from the relevant authority, the said expenses have been shown as an exceptional item.

(iv) In case of subsidiary NCDEX e Markets Limited (NeML), during the nine months ended December 31, 2023, exceptional Income of Rs 44 lakh is on account of income booked for recovery of Preincorporation and other expenses incurred on behalf of newly incorporated JV, prior to receipt of approval from Regulatory authorities.

For and on behalf of the Board of Directors

Arun Raste

Managing Director & Chief Executive Officer DIN - 08561128 CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat Phone No.: +91-79-68138700 || Fax: +91-79-68138725 || CIN: L24230GJ1984PLC007440 Email Id: complianceofficer@concordbiotech.com | Website: www. concordbiotech.com Regd. Office & Plant: 1482-86, Trasad Road, Dholka, District: Ahmedabad - 382225, Gujarat, India Phone No.: +91-2714-222604, 398200 || Fax: +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

		Standal	one (Unaud	ited)	Consoli	dated (Una	udited)
SI. No	Particulars	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022
1.	Total Income from Operations	24,079.65	69,796.98	24,068.29	24,079.65	69,796.98	24,068.29
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,455.30	20,751.75	7,907.55	7,757.27	21,308.69	7,736.83
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(64.87)	(40.36)	17.94	(64.87)	(40.36)	17.94
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.		1,28,151.88		745	1,28,151.88	

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly / Nine Months Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com

19.84

19.84

7.13

7.13

operations - Not Annualised)

1) Basic

2) Diluted

PSP

Earnings Per Share (Face Value of Rs. 1/ each) (for continuing and discontinued

(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules /AS Rules, whichever is applicable.

(c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 08, 2024. For and on behalf of board of directors of Concord Biotech Limited

Place: Ahmedabad Ankur Vaid Date: Fennruary 8, 2024 Joint Managing Director & CEO - DIN: 01857225

> **PSP Projects Limited** CIN:L45201GJ2008PLC054868

Registered Office: PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058 Website: www.pspprojects.com Extract of Unaudited Consolidated Financial Results for the Quarter and

Nine months ended December 31, 2023 (₹ in Lakhs) Consolidated Quarter Ended Nine Months Ended 31.12.2023 31.12.2022 31.12.2023 Particular (Unaudited) (Unaudited) (Unaudited) No. Total Income from Operations 71,118.31 50,659.07 1,85,617.46 Net Profit for the period (before Tax, Exceptional and Extraordinary 4,204.40 4,824.99 14,468.84 Items and Share of Profit/(Loss) from Joint Venture) Net Profit for the period (after tax, Exceptional and Extraordinary 3,106.66 3,532.82 10,737.75 Items before Share of Profit/(Loss) from Joint Venture) Net Profit for the period (after tax, Exceptional and Extraordinary 3,536.01 10,745.06 3,108.32 Items and Share of Profit/(Loss) from Joint Venture) Total Comprehensive Income for the period [Comprising Profit for 3,538.31 10,751.96 3,110.62 the period (after tax) and Other Comprehensive Income (after tax)] Paid-up Equity Share Capital - Face Value ₹10/- each 3,600.00 3,600.00 3,600.00 Other Equity excluding Revaluation Reserves

Notes:

Basic

Diluted

1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09, 2024. (₹ in Lakhs) Additional information on Unaudited Standalone Financial Results are as follows:

Standalone Quarter Ended Nine Months Ended 31.12.2023 31.12.2022 31.12.2023 Particular (Unaudited) (Unaudited) (Unaudited) 69,661.92 49,739.28 Revenue from Operations 1,81,332.80 Profit/(Loss) before tax and Exceptional item 4,397.86 4,815.39 14,636.12 Profit/(Loss) after tax and Exceptional item 3,529.50 3,251.85 10,864.77

3. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: www.pspprojects.com) For and on behalf of Board of Directors of PSP Projects Limited

Prahaladbhai S. Patel Place: Ahmedabad Chairman, Managing Director & CEO Date: February 9, 2024 DIN: 00037633



Earnings Per Share of ₹ 10/-each (in ₹) (Not Annualised)

Regd.Office: AVINISHA TOWER, MEHADIA CHOWK, DHANTOLI, NAGPUR - 440 012. Ph no.0712-6663999 Website: www.berarfinance.com E-mail: investor.relations@berarfinance.com

CIN:U65929MH1990PLC057829

8.63

8.63

9.82

9.82

29.85

29.85

Extract of Financial Results for the quarter ended December 31, 2023 [Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)] (₹ in Lakhs, except per equity share data and Debt Equity Ratio)

Sr. No.	PARTICULARS	Quarter ended Dec. 31, 2023	Quarter ended Dec. 31, 2022	Year ended March 31,2023
(40.		UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations	6662.90	6259.69	21788.93
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
4	Net Profit /(Loss)for the period after tax (after Exceptional and/or Extraordinary items#)	517.58	892.62	1708.12
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	522.11	897.90	1709.27
6	Paid -up Equity Share Capital	1233.68	1233.68	1233.68
7	Reserves (excluding Revaluation Reserve)	11895.60	10345.60	11895.60
8	Securities Premium Account	14123.94	14123.94	14123.94
9	Net worth (Including Retained earnings and ESOP)	29113.77	27579.63	27523.60
10	Paid up Debt Capital/ Outstanding Debt	92679.81	85014.88	83190.22
11	Outstanding Redeemable Preference Shares	NA	NA	NA
12	Debt Equity Ratio	3.18	3.08	3.02
13	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)*			
	a) Basic	4.20	7.24	13.85
100000	b) Diluted	4.18	7.24	13.79
14		NA	NA	NA
15	Debenture Redemption Reserve	NA	NA	NA
16		NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA.	NA

Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance

* Not annualised for quarter ended December 31, 2023 and December 31, 2022.

 a) The above Results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on February 09, 2024.

b) The above is an extract of the detailed format of financial results filed with the BSE Limited ("Stock Exchange") under Regulation 52 of the SEBI Listing Regulations. The full format of the financial results is available on the website of the Stock Exchange i.e www.bscindia.com and on the website of the Company i.e www.berarfinance.com

c) For the other line items referred in regulation 52 (4) of the SEBI Listing Regulations, pertinent disclosures have been made to BSE Limited and can be accessed on www.bseindia.com. and on the website of the Company i.e

d) This Extract of Financial Results has been prepared in accordance with the requirement of Regulation 52 of the SEBI Listing Regulations read with Operational Circular bearing reference no. SEBI /HO /DDHS /DDHS Div1 /P /CIR/2022/0000000103 dated July 29, 2022 as amended ("Circular").

Berar Finance Limited

(Sandeep Jawanjal) Managing Director

For and on behalf of Board of Directors of

financialexp.epap.in

Place: Nagpur Date: February 09, 2024

DIN: 01490054 Lucknow

Place: Mumbai

Date: February 9, 2024

(Rs. In lakhs except per share data)



Aster DM Healthcare Limited

CIN: L85110KA2008PLC147259

Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India. Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023 (Amount in INR crores except per share data)

			Conso	lidated					Stand	dalone		
Particulars		Quarter ende	d	Nine Mon	iths ended	Year ended		Quarter ende	d	Nine Mor	nths ended	Year ended
	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
Total income	3,718.56	3,325.22	3,200.67	10,268.35	8,734.78	12,011.13	537.83	529.69	409.33	1,536.24	1,141.82	1,583.51
Net profit/ (loss) before tax	233.46	(5.16)	173.44	301.55	329.30	535.08	53.19	56.69	41.44	162.70	128.28	182.33
Net profit/ (loss) after tax	209.22	(15.33)	159.03	213.74	292.90	475.49	53.19	59.06	34.58	165.07	121.42	
Total Comprehensive Income/ (loss)	208.96	12.75	191.59	238.90	466.88	674.44	53.19	59.06	34.58	165.07	121.42	173.70
Equity Share Capital	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52
Other Equity			- 8	- 8	-	3,948.55			- 8	- 3	-	2,631.04
Earnings per share (Face value of INR 10 each)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised
Basic	3.60	(0.62)	2.80	3.08	5.11	8.54	1.07	1.19	0.70	3.32	2.44	3.48
Diluted	3.60	(0.62)	2.80	3.08	5.10	8.53	1.07	1.19	0.69	3.31	2.44	3.48

The unaudited consolidated and standalone financial results of the Company for the guarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee on February 08, 2024 and approved by the Board of Directors at its meeting held on February 08, 2024.

The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial statements is made available on the Company's website at www.asterdmhealthcare.com/investors and stock exchange website at BSE https://www.bseindia.com/ and NSE https://www.nseindia.com/.

◆The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

For Aster DM Healthcare Limited Sd/-Alisha Moopen **Deputy Managing Director** DIN: 02432525

Dedicated To Life

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481 Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com

Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023 **Rupees in Million**

CIN: L24230GJ1995PLC025878

				Corresponding	Year to date		
				3 Months	figures for	Year to date	
Sr. No	. Particulars			ended	the current	figures for the	
51. 140	i di dicalai 3	3 Months	Preceding 3	31/12/2022 in	period	previous	Previous year
		ended	Months ended	the previous	ended	period ended	ended
		31/12/2023	30/09/2023	year	31/12/2023	31/12/2022	31/03/2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1	Total income from operations	45,052	43,688	42,571	140,136	122,269	172,374
2	Net Profit for the period before exceptional items and tax	9,255	10,072	7,801	32,761	21,068	31,939
3	Net Profit for the period after exceptional items but before tax	9,255	10,072	7,801	32,619	21,039	25,897
4	Net Profit for the period from continuing operations	7,678	8,017	6,225	26,574	16,661	19,649
5	Profit/ [Loss] after tax from discontinued operations	218	(10)	4	198	(24)	(46)
6	Net Profit for the period after tax and Non-Controlling Interest	7,896	8,007	6,229	26,772	16,637	19,603
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	8,099	7,446	5,479	26,476	13,444	16,459
8	Paid-up equity share capital (Face value Re. 1/-)	1,012	1,012	1,012	1,012	1,012	1,012
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)						174,146
10	Earnings per share for continuing operations (not annualised for the quarter and nine months)						
a	Basic (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
b	Diluted (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)						
a	Basic (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
b	Diluted (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
Note:					-		

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com]. By Order of the Board,

For Zydus Lifesciences Limited,

Dr. Sharvil P. Patel Managing Director DIN: 00131995



National Commodity & Derivatives Exchange Limited CIN: U51909MH2003PLC140116

Regd Office: Akruti Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West,

Mumbai, Maharashtra 400078

Ph: 022-66406789 **Email:** askus@ncdex.com | **Website:** www.ncdex.com

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023 (Rs. In lakhs)

SI. No.	Particulars	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)
1.	Total Income from operations	1,210	1,167	4,133	3,313	3,430	10,209
2.	Net profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	(1,438)	(1,415)	(3,619)	(1,311)	(1,512)	(3,275)
3.	Net profit/ (Loss) for the period before Tax (after Exceptional and/or Extraordinary items#)	1,268	(1,415)	(323)	(1,311)	(1,548)	(3,231)
4.	Net profit/ (Loss) for the period after Tax (after Exceptional and/or Extraordinary items#)	1,488	(1,045)	321	(1,126)	(1,113)	(2,497)
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	1,521	(1,065)	357	(1,107)	(1,164)	(2,505)
6.	Equity Share Capital	5,068	5,068	5,068	5,068	5,068	5,068
7.	Reserves (excluding Revaluation Reserve) as shown in Audited Balance Sheet of the previous year	-	-	-	-	-	-
8.	Earnings Per Share (FV ₹ 10 each) (for continuing and						

Notes:

1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure

2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.

3 #(i) In standalone financial statements, during the quarter ended December 31,2023, the Exchange has received excess contribution of Rs.15 lakh and Rs. 590 lakh during the half year ended September 30,2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd.(NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31,2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment

(2.06)

(2.06)

0.63

0.63

e-Markets Limited (NeML), to its wholly owned subsidiary, NCCL, for a consideration of Rs. 3,000.80 lakh. The profit earned on the said stake sale of Rs. 2,691 lakh has been credited to the statement of profit and loss and shown as an exceptional item.

(iii) In case of subsidiary NCDEX e Markets Limited (NeML), NeML has incurred expenses of Rs. 36 Lakhs on newly incorporated Joint Venture during the nine months ended December 31, 2022. As the approval for commencement of business is awaited from the relevant authority, the said expenses have been shown as an exceptional item.

(iv) In case of subsidiary NCDEX e Markets Limited (NeML), during the nine months ended December 31, 2023, exceptional Income of Rs 44 lakh is on account of income booked for recovery of Preincorporation and other expenses incurred on behalf of newly incorporated JV, prior to receipt of approval from Regulatory authorities.

(2.15)

(2.15)

(2.11)

(2.11)

(4.69)

(4.69)

Consolidated

Arun Raste

CONCORD BIOTECH LIMITED

B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat Phone No.: +91-79-68138700 || Fax: +91-79-68138725 || CIN: L24230GJ1984PLC007440 Email Id: complianceofficer@concordbiotech.com | Website: www. concordbiotech.com Regd. Office & Plant: 1482-86, Trasad Road, Dholka, District: Ahmedabad - 382225, Gujarat, India Phone No.: +91-2714-222604, 398200 || Fax: +91-2714-222504

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

Ť	The state of the s	Standal	one (Unaud	ited)	Consoli	dated (Una	udited)
SI. No	Particulars	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022
1	Total Income from Operations	24,079.65	69,796.98	24,068.29	24,079.65	69,796.98	24,068.29
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,455.30	20,751.75	7,907.55	7,757.27	21,308.69	7,736.83
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(64.87)	(40.36)	17.94	(64.87)	(40.36)	17.94
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.		1,28,151.88			1,28,151.88	
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations - Not Annualised)						
	1) Basic	7.13	19.84	7.56	7.41	20.37	7.40
	2) Diluted	7.13	19.84	7.56	7.41	20.37	7.40

Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com (b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with

Ind-AS Rules /AS Rules, whichever is applicable. (c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 08, 2024.

For and on behalf of board of directors of Concord Biotech Limited Place: Ahmedabad **Ankur Vaid**

Date: Fennruary 8, 2024 Joint Managing Director & CEO - DIN: 01857225

> **PSP Projects Limited** CIN:L45201GJ2008PLC054868

Registered Office: PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058 Website: www.pspprojects.com Extract of Unaudited Consolidated Financial Results for the Quarter and

Nine months ended December 31, 2023 (₹ in Lakhs) Consolidated Quarter Ended Nine Months Ended 31.12.2023 31.12.2022 31.12.2023 Particular (Unaudited) (Unaudited) (Unaudited) No. Total Income from Operations 71,118.31 50,659.07 1,85,617.46 Net Profit for the period (before Tax, Exceptional and Extraordinary 4,204.40 4,824.99 14,468.84 Items and Share of Profit/(Loss) from Joint Venture) 10,737.75 Net Profit for the period (after tax, Exceptional and Extraordinary 3,106.66 3,532.82 Items before Share of Profit/(Loss) from Joint Venture) Net Profit for the period (after tax, Exceptional and Extraordinary 3,108.32 3,536.01 10,745.06 Items and Share of Profit/(Loss) from Joint Venture) Total Comprehensive Income for the period [Comprising Profit for 3,110.62 3,538.31 10,751.96 the period (after tax) and Other Comprehensive Income (after tax)) Paid-up Equity Share Capital - Face Value ₹10/- each 3,600.00 3,600.00 3,600.00

Notes: 1. The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their

respective meetings held on February 09, 2024. (₹ in Lakhs) 2. Additional information on Unaudited Standalone Financial Results are as follows:

Standalone Quarter Ended Nine Months Ended 31.12.2023 31.12.2022 31.12.2023 Particular (Unaudited) (Unaudited) (Unaudited) Revenue from Operations 69,661.92 49,739.28 1,81,332.80 Profit/(Loss) before tax and Exceptional item 4,397.86 4,815.39 14,636.12 Profit/(Loss) after tax and Exceptional item 3,251.85 3,529.50 10,864.77

3. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33

of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL: www.bseindia.com), National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: www.pspprojects.com) For and on behalf of Board of Directors of PSP Projects Limited

Prahaladbhai S. Patel Place: Ahmedabad Chairman, Managing Director & CEO Date: February 9, 2024 DIN: 00037633



Other Equity excluding Revaluation Reserves

Earnings Per Share of ₹ 10/-each (in ₹) (Not Annualised)

PSP

Basic

Diluted

Regd.Office: AVINISHA TOWER, MEHADIA CHOWK, DHANTOLI, NAGPUR - 440 012. Ph no.0712-6663999 Website: www.berarfinance.com E-mail: investor.relations@berarfinance.com

CIN:U65929MH1990PLC057829

8.63

8.63

9.82

9.82

29.85

29.85

[Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)] (₹ in Lakhs, except per equity share data and Debt Equity Ratio)

Sr.	PARTICULARS	Quarter ended Dec. 31, 2023		Year ended March 31,2023
No.		UNAUDITED	UNAUDITED	AUDITED
1	Total Income from Operations	6662.90	6259.69	21788.93
2	Net Profit/(Loss) for the period (before Tax, Exceptional and/or Extraordinary items #)	741.10	1000.83	2172.78
3	Net Profit/(Loss) for the period before tax (after Exceptional and/or Extraordinary items #)	741.10	1000.83	2172,78
4	Net Profit /(Loss)for the period after tax (after Exceptional and/or Extraordinary items#)	517.58	892.62	1708.12
5	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	522.11	897.90	1709.27
6	Paid -up Equity Share Capital	1233.68	1233.68	1233.68
7	Reserves (excluding Revaluation Reserve)	11895.60	10345.60	11895.60
8	Securities Premium Account	14123.94	14123.94	14123.94
9	Net worth (Including Retained earnings and ESOP)	29113.77	27579.63	27523.60
10	Paid up Debt Capital/ Outstanding Debt	92679.81	85014.88	83190.22
11	Outstanding Redeemable Preference Shares	NA	NA	NA.
12	Debt Equity Ratio	3.18	3.08	3.02
13	Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)*	2/252	0.550	24-24
- 1	a) Basic	4.20	7.24	13.85
	b) Diluted	4.18	7.24	13.79
	Capital Redemption Reserve	NA	NA	NA
	Debenture Redemption Reserve	NA	NA	NA
	Debt Service Coverage Ratio	NA	NA	NA
17	Interest Service Coverage Ratio	NA	NA	NA

Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind AS Rules.

Not annualised for quarter ended December 31, 2023 and December 31, 2022.

/CIR/2022/0000000103 dated July 29, 2022 as amended ("Circular").

a) The above Results have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on February 09, 2024.

b) The above is an extract of the detailed format of financial results filed with the BSE Limited ("Stock Exchange") under Regulation 52 of the SEBI Listing Regulations. The full format of the financial results is available on the website of the Stock Exchange i.e www.bseindia.com and on the website of the Company i.e www.berarfinance.com

c) For the other line items referred in regulation 52 (4) of the SEBI Listing Regulations, pertinent disclosures have been made to BSE Limited and can be accessed on www.bseindia.com. and on the website of the Company i.e.

www.berarfinance.com d) This Extract of Financial Results has been prepared in accordance with the requirement of Regulation 52 of the SEBI Listing Regulations read with Operational Circular bearing reference no. SEBI /HO /DDHS /DDHS Div1 /P

> For and on behalf of Board of Directors of Berar Finance Limited

> > (Sandeep Jawanjal) Managing Director DIN: 01490054

Place: Nagpur Date: February 09, 2024

financialexp.epapr.in

Place: Mumbai

Date: February 9, 2024

Place: Dubai Date: February 08, 2024

Place: Ahmedabad

Date: February 9, 2024

Standalone

discontinued operations) 2.94 1. Basic (₹): Not annualised

2.94 2. Diluted (₹): Not annualised

Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financials are available on our website www.ncdex.com

and the same is credited to the statement of profit and loss and shown as an Exceptional item. (ii) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has sold 8.71% (31 lakh equity share) of its stake in its subsidiary, NCDEX

For and on behalf of the Board of Directors

Managing Director & Chief Executive Officer DIN - 08561128



Aster DM Healthcare Limited

CIN: L85110KA2008PLC147259

Registered Office: No.1785, Sarjapur Road, Sector -1, HSR Layout, Ward No.174, Agara Extension, Bengaluru-560102, Karnataka, India. Tel: +91 484 6699999, Website: www.asterdmhealthcare.com Email: cs@asterdmhealthcare.com

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND NINE MONTHS ENDED DECEMBER 31, 2023

									(Amour	nt in INR cror	es except pe	er share data)	
	T		Conso	lidated		-			Stan	dalone			
Particulars	culars Quarter ended					Quarter ended Nine Months ended Year ended			Quarter ende	d	Nine Months ended		Year ended
	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	31-Dec-23	30-Sep-23	31-Dec-22	31-Dec-23	31-Dec-22	31-Mar-23	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)	
Total income	3,718.56	3,325.22	3,200.67	10,268.35	8,734.78	12,011.13	537.83	529.69	409.33	1,536.24	1,141.82	1,583.51	
Net profit/ (loss) before tax	233.46	(5.16)	173.44	301.55	329.30	535.08	53.19	56.69	41.44	162.70	128.28	182.33	
Net profit/ (loss) after tax	209.22	(15.33)	159.03	213.74	292.90	475.49	53.19	59.06	34.58	165.07	121.42	173.29	
Total Comprehensive Income/ (loss)	208.96	12.75	191.59	238.90	466.88	674.44	53.19	59.06	34.58	165.07	121.42	173.70	
Equity Share Capital	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	499.52	
Other Equity	-	-	D -	7 -	D - 5	3,948.55	- 55	70 - 97	- 1	- 7	- //	2,631.04	
Earnings per share (Face value of INR 10 each)	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Not Annualised	Annualised	
Basic	3.60	(0.62)	2.80	3.08	5.11	8.54	1.07	1.19	0.70	3.32	2.44	3.48	
Diluted	3.60	(0.62)	2.80	3.08	5.10	8.53	1.07	1.19	0.69	3.31	2.44	3.48	

The unaudited consolidated and standalone financial results of the Company for the guarter and nine months ended December 31, 2023 have been reviewed by the Audit Committee on February 08. 2024 and approved by the Board of Directors at its meeting held on February 08, 2024.

•The above is an extract of the detailed format of quarterly financial results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the quarterly financial statements is made available on the Company's website at www.asterdmhealthcare.com/investors and stock exchange website at BSE https://www.bseindia.com/ and NSE https://www.nseindia.com/.

The Statement has been subjected to limited review by Deloitte Haskins & Sells, the statutory auditor of the Company. The review report of the auditor is unmodified.

For Aster DM Healthcare Limited

Alisha Moopen **Deputy Managing Director** DIN: 02432525

Dedicated To Life

Date: February 08, 2024

Place: Dubai

Zydus Lifesciences Limited [formerly known as Cadila Healthcare Limited]

Registered Office: Zydus Corporate Park, Scheme No. 63, Survey No. 536, Khoraj (Gandhinagar), Near Vaishnodevi Circle, Sarkhej- Gandhinagar Highway, Ahmedabad - 382481 Tel. No.: (+91-79) 4804 0000 Website: www.zyduslife.com CIN: L24230GJ1995PLC025878

Extract of Consolidated Unaudited Financial Results for the Quarter and Nine Months Ended December 31, 2023 Rupees in Million

	9			Corresponding	Year to date	3	0
ı				3 Months	figures for	Year to date	
Sr. No.	Particulars			ended	the current	figures for the	
l .		3 Months		31/12/2022 in		previous	Previous year
ı		ended	Months ended		ended	period ended	ended
ı		31/12/2023		year	31/12/2023		31/03/2023
		(Unaudited)		(Unaudited)	(Unaudited)		(Audited)
1	Total income from operations	45,052	43,688	42,571	140,136	122,269	172,374
2	Net Profit for the period before exceptional items and tax	9,255	10,072	7,801	32,761	21,068	31,939
3	Net Profit for the period after exceptional items but before tax	9,255	10,072	7,801	32,619	21,039	25,897
4	Net Profit for the period from continuing operations	7,678	8,017	6,225	26,574	16,661	19,649
5	Profit/ [Loss] after tax from discontinued operations	218	(10)	4	198	(24)	(46)
6	Net Profit for the period after tax and Non-Controlling Interest	7,896	8,007	6,229	26,772	16,637	19,603
7	Total Comprehensive Income for the period after tax and Non-Controlling Interest	8,099	7,446	5,479	26,476	13,444	16,459
8	Paid-up equity share capital (Face value Re. 1/-)	1,012	1,012	1,012	1,012	1,012	1,012
9	Reserves excluding Revaluation Reserve (i.e. Other Equity)						174,146
10	Earnings per share for continuing operations (not annualised for the quarter and nine months)						
a	Basic (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
b	Diluted (Rs.)	7.59	7.92	6.15	26.25	16.39	19.35
11	Earnings per share for continuing & discontinued operations (not annualised for the quarter and nine months)						
a	Basic (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
b	Diluted (Rs.)	7.80	7.91	6.15	26.45	16.36	19.30
Note:							

[1] The above is an extract of the detailed format of Quarterly/ Nine Monthly Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI [Listing Obligations and Disclosure Requirements] Regulations, 2015. The full format of the Quarterly/ Nine Monthly Financial Results are available on the Company's website: www.zyduslife.com, on the website of BSE [www.bseindia.com] and on the website of NSE [www.nseindia.com].

> By Order of the Board, For Zydus Lifesciences Limited,

> > Dr. Sharvil P. Patel Managing Director

> > > DIN: 00131995

Date: February 9, 2024 Place: Ahmedabad



National Commodity & Derivatives Exchange Limited

CIN: U51909MH2003PLC140116

Regd Office: Akruti Corporate Park, 1st Floor, L.B.S. Road, Near G.E.Garden, Kanjurmarg West,

Mumbai, Maharashtra 400078

Website: www.ncdex.com **Ph**: 022-66406789 Email: askus@ncdex.com

Extract of Standalone and Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023 (Rs. In lakhs)

			Standalone	9	Consolidated				
SI. No.	Particulars	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023	Quarter ended 31.12.2023	Quarter ended 31.12.2022	Nine months ended 31.12.2023		
		(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)		
1.	Total Income from operations	1,210	1,167	4,133	3,313	3,430	10,209		
2.	Net profit/ (Loss) for the period (before Tax, Exceptional and/or Extraordinary items#)	(1,438)	(1,415)	(3,619)	(1,311)	(1,512)	(3,275)		
3.	Net profit/ (Loss) for the period before Tax (after Exceptional and/or Extraordinary items#)	1,268	(1,415)	(323)	(1,311)	(1,548)	(3,231)		
4.	Net profit/ (Loss) for the period after Tax (after Exceptional and/or Extraordinary items#)	1,488	(1,045)	321	(1,126)	(1,113)	(2,497)		
5.	Total Comprehensive Income for the period [Comprising Profit/(Loss) for the period (after tax) and other Comprehensive Income (after tax)]	1,521	(1,065)	357	(1,107)	(1,164)	(2,505)		
6.	Equity Share Capital	5,068	5,068	5,068	5,068	5,068	5,068		
7.	Reserves (excluding Revaluation Reserve) as shown in Audited Balance Sheet of the previous year	-	-		-	-	-		
8.	Earnings Per Share (FV ₹ 10 each) (for continuing and discontinued operations) 1. Basic (₹): Not annualised 2. Diluted (₹): Not annualised	2.94 2.94	(2.06) (2.06)	0.63 0.63	(2.15) (2.15)	(2.11) (2.11)	(4.69) (4.69)		

Notes:

- 1 The above is an extract of the detailed format of Standalone and Consolidated Financial Results vide Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the Standalone and Consolidated Financials are available on our website www.ncdex.com
- 2 The above Standalone and Consolidated Financial Results have been reviewed by the Audit Committee in its meeting held on February 8, 2024 and approved by the Board of Directors in their meeting held on February 9, 2024.
- 3 #(i) In standalone financial statements, during the quarter ended December 31,2023, the Exchange has received excess contribution of Rs.15 lakh and Rs. 590 lakh during the half year ended September 30,2023 from Core SGF (post tax liability of Core SGF) from its subsidiary company, National Commodity Clearing Ltd.(NCCL) aggregating to Rs. 605 lakh for the nine months period ended December 31,2023, due to revision in computation of Core Settlement Guarantee Fund (SGF) in Commodity Derivatives Segment and the same is credited to the statement of profit and loss and shown as an Exceptional item.

(ii) In standalone financial statements, during the quarter ended December 31, 2023, the Exchange has sold 8.71% (31 lakh equity share) of its stake in its subsidiary, NCDEX e-Markets Limited (NeML), to its wholly owned subsidiary, NCCL, for a consideration of Rs. 3,000.80 lakh. The profit earned on the said stake sale of Rs. 2,691 lakh has been credited to the statement of profit and loss and shown as an exceptional item.

(iii) In case of subsidiary NCDEX e Markets Limited (NeML), NeML has incurred expenses of Rs. 36 Lakhs on newly incorporated Joint Venture during the nine months ended

December 31, 2022. As the approval for commencement of business is awaited from the relevant authority, the said expenses have been shown as an exceptional item. (iv) In case of subsidiary NCDEX e Markets Limited (NeML), during the nine months ended December 31, 2023, exceptional Income of Rs 44 lakh is on account of income booked for recovery of Preincorporation and other expenses incurred on behalf of newly incorporated JV, prior to receipt of approval from Regulatory authorities.

For and on behalf of the Board of Directors

Arun Raste

Managing Director & Chief Executive Officer DIN - 08561128 B/1601-1602, B Wing, Mondeal Heights, Iscon Cross Road, S.G. Highway, Ahmedabad - 380015, Gujarat Phone No.: +91-79-68138700 || Fax: +91-79-68138725 || CIN: L24230GJ1984PLC007440 Email Id : complianceofficer@concordbiotech.com || Website : www. concordbiotech.com Regd. Office & Plant: 1482-86, Trasad Road, Dholka, District: Ahmedabad - 382225, Gujarat, India Phone No.: +91-2714-222604, 398200 || Fax: +91-2714-222504

CONCORD BIOTECH LIMITED

STATEMENT OF STANDALONE/CONSOLIDATED UNAUDITED FINANCIAL RESULTS FOR THE THIRD QUARTER AND NINE MONTHS ENDED ON DECEMBER 31, 2023

ĺ.,	70	·		(Rs. In Ia	akhs exce	pt per sha	re data)
	Particulars	Standalone (Unaudited)			Consolidated (Unaudited)		
SL No		Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022	Quarter ended on 31/12/2023	Nine Months ended on 31/12/2023	Quarter ended on 31/12/2022
1	Total Income from Operations	24,079.65	69,796.98	24,068.29	24,079.65	69,796.98	24,068.29
2	Net Profit / (Loss) for the period (before Tax, Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
3	Net Profit / (Loss) for the period before tax (after Exceptional and / or Extraordinary items#)	10,008.37	27,827.50	10,624.99	10,310.34	28,384.44	10,454.27
4	Net Profit / (Loss) for the period after tax (after Exceptional and / or Extraordinary items#)	7,455.30	20,751.75	7,907.55	7,757.27	21,308.69	7,736.83
5	Total Comprehensive Income for the period [Comprising Profit / (Loss) for the period (after tax) and Other Comprehensive Income (after tax)]	(64.87)	(40.36)	17.94	(64.87)	(40.36)	17.94
6	Equity Share Capital	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16	1,046.16
7	Reserves (excluding Revaluation Reserve) as shown in the Audited Balance Sheet of the previous year.		1,28,151.88		1,28,151.88		
8	Earnings Per Share (Face Value of Rs.1/- each) (for continuing and discontinued operations - Not Annualised)		1DC=20924	2		()	
	1) Basic	7.13	19.84	7.56	7.41	20.37	7.40
	2) Diluted	7.13	19.84	7.56	7.41	20.37	7.40

Notes : (a) The above is an extract of the detailed format of Unaudited Quarterly / Nine Months Standalone and Consolidated Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full format of the said Quarterly / Nine Months Standalone and Consolidated Financial Results are available on the websites of the Stock Exchange(s) i.e. www.bseindia.com and www.nseindia.com and the listed entity i.e. www.concordbiotech.com

(b) # - Exceptional and / or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind-AS Rules /AS Rules, whichever is applicable.

(c) The above Unaudited Standalone and Consolidated Financial Results were reviewed by the Audit Committee and approved by the Board of Directors of the Company at their meeting held on February 08, 2024.

For and on behalf of board of directors of Concord Biotech Limited Place: Ahmedabad Ankur Vaid

PSP

Date: Fennruary 8, 2024

PSP Projects Limited

Joint Managing Director & CEO - DIN: 01857225

CIN:L45201GJ2008PLC054868 Registered Office: PSP House, Opp. Celesta Courtyard, Opp. Lane of Vikram Nagar Colony, Iscon-Ambli Road, Ahmedabad - 380 058

Extract of Unaudited Consolidated Financial Results for the Quarter and Nine months ended December 31, 2023 (₹ in Lakhs)

Website: www.pspprojects.com

		Consolidated				
		Quarte	r Ended			
Sr. No.	Particular		31.12.2022 (Unaudited)			
1.	Total Income from Operations	71,118.31	50,659.07	1,85,617.46		
2.	Net Profit for the period (before Tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	4,204.40	4,824.99	14,468.84		
3.	Net Profit for the period (after tax, Exceptional and Extraordinary Items before Share of Profit/(Loss) from Joint Venture)	3,106.66	3,532.82	10,737.75		
4.	Net Profit for the period (after tax, Exceptional and Extraordinary Items and Share of Profit/(Loss) from Joint Venture)	3,108.32	3,536.01	10,745.06		
5.	Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive Income (after tax)]	3,110.62	3,538.31	10,751.96		
6.	Paid-up Equity Share Capital - Face Value ₹10/- each	3,600.00	3,600.00	3,600.00		
7.	Other Equity excluding Revaluation Reserves		-	12		
8.	Earnings Per Share of ₹ 10/-each (in ₹) (Not Annualised)			W1 + 2 Y - 2		
	Basic	8.63	9.82	29.85		
	Diluted	8.63	9.82	29.85		

Notes:

 The above results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meetings held on February 09, 2024.

(₹ in Lakhs) Additional information on Unaudited Standalone Financial Results are as follows: Standalone Quarter Ended Nine Months Ended 31.12.2023 31.12.2022 31.12.2023 Particular (Unaudited) (Unaudited) (Unaudited) Revenue from Operations 69,661.92 49,739.28 1,81,332.80 Profit/(Loss) before tax and Exceptional item 14,636.12 4,397.86 4,815.39 Profit/(Loss) after tax and Exceptional item 3,529.50 3,251.85 10,864.77

3. The above is an extract of the detailed format of Financial Results filed with the Stock Exchanges under Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The full results for the Quarter and Nine months ended December 31, 2023 are available on the website of BSE Limited (URL: www.bseindia.com) National Stock Exchange of India Limited (URL: www.nseindia.com) and on company's website (URL: www.pspprojects.com) For and on behalf of Board of Directors of PSP Projects Limited

Place: Ahmedabad Date: February 9, 2024

16 Debt Service Coverage Ratio

Place: Nagpur

Date: February 09, 2024

17 Interest Service Coverage Ratio

Prahaladbhai S. Patel Chairman, Managing Director & CEO DIN: 00037633



Regd.Office: AVINISHA TOWER, MEHADIA CHOWK, DHANTOLI, NAGPUR - 440 012. Ph no.0712-6663999 Website: www.berarfinance.com E-mail: investor.relations@berarfinance.com

CIN:U65929MH1990PLC057829

Extract of Financial Results for the quarter ended December 31, 2023 [Regulation 52(8) read with Regulation 52(4) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (SEBI Listing Regulations)] (₹ in Lakhs, except per equity share data and Debt Equity Ratio)

Quarter ended Quarter ended Year ended PARTICULARS Dec. 31, 2023 Dec. 31, 2022 March 31,2023 UNAUDITED UNAUDITED AUDITED 6662.90 6259.69 1 Total Income from Operations 21788.93 2 Net Profit/(Loss) for the period (before Tax, Exceptional 741.10 1000.83 2172.78 and/or Extraordinary items #) 3 Net Profit/(Loss) for the period before tax (after Exceptional) 1000.83 2172.78 and/or Extraordinary items #) 741.10 4 Net Profit /(Loss)for the period after tax (after Exceptional 517.58 892.62 1708.12 and/or Extraordinary items#) Total Comprehensive Income for the period [Comprising Profit for the period (after tax) and Other Comprehensive 522.11 897,90 1709.27 Income (after tax)] 6 Paid -up Equity Share Capital 1233.68 1233.68 1233.68 7 Reserves (excluding Revaluation Reserve) 11895.60 10345.60 11895.60 8 Securities Premium Account 14123.94 14123.94 14123.94 9 Net worth (Including Retained earnings and ESOP) 29113.77 27579.63 27523.60 10 Paid up Debt Capital/ Outstanding Debt 85014.88 83190.22 92679.81 11 Outstanding Redeemable Preference Shares NA NA NA 3.08 3.02 12 Debt Equity Ratio 3.18 13 Earnings Per Share (of Rs.10/- each) (for continuing and discontinued operations)* 4.20 7.24 13.85 4.18 7.24 b) Diluted 13.79 NA 14 Capital Redemption Reserve NA NA NA 15 Debenture Redemption Reserve NA NA

Exceptional and/or Extraordinary items adjusted in the Statement of Profit and Loss in accordance with Ind AS Rules.

* Not annualised for quarter ended December 31, 2023 and December 31, 2022.

/CIR/2022/0000000103 dated July 29, 2022 as amended ("Circular").

a) The above Results have been reviewed by the Audit Committee and subsequently approved by the Board of

Directors at their respective meetings held on February 09, 2024. b) The above is an extract of the detailed format of financial results filed with the BSE Limited ("Stock Exchange") under Regulation 52 of the SEBI Listing Regulations. The full format of the financial results is available on the website of the Stock Exchange i.e www.bseindia.com and on the website of the Company i.e

) For the other line items referred in regulation 52 (4) of the SEBI Listing Regulations, pertinent disclosures have

been made to BSE Limited and can be accessed on www.bseindia.com. and on the website of the Company i.e www.berarfinance.com d) This Extract of Financial Results has been prepared in accordance with the requirement of Regulation 52 of the SEBI Listing Regulations read with Operational Circular bearing reference no. SEBI /HO /DDHS /DDHS Div1 /P

> For and on behalf of Board of Directors of Berar Finance Limited

NA

(Sandeep Jawanjal) Managing Director DIN: 01490054

NA

NA

NA



financialexp.epapr.in

Place: Mumbai

Date: February 9, 2024





